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ABSTRACT 
Leena Kämppi, Delays in the treatment of status epilepticus – effect on outcome. 
University of Helsinki: Doctoral Programme in Clinical Research 
 
Status epilepticus (SE), i.e. prolonged epileptic seizure, is a life-threatening medical 
emergency, which is associated with high mortality and morbidity. International 
guidelines suggest early and efficient treatment. Thus, long duration of SE is one of the 
main predictors of poor prognosis and the only prognostic factor that can be affected 
by shortening the delays in the treatment. However, studies on delays, 
implementation of treatment guidelines and the effect of delays on outcome are 
scarce.  
 
The aim of this thesis was to systematically investigate delays in the treatment of SE 
and factors related to the delays along the whole treatment chain. We also aimed at 
clarifying the effect of delays on the outcome and at identifying the significant delays 
related to outcome in order to propose evidence-based targets for streamlining the SE 
treatment protocol.  
 
The material of this retrospective study consists of 82 consecutive SE patients treated 
in a tertiary hospital emergency department over two years. Delays, patient 
characteristics and parameters related to treatment chain were identified and their 
relations, correlations and effects were investigated.  
 
The results of this thesis reveal that the delays in the treatment of SE are unacceptably 
long and exceed markedly the suggested time frames in the guidelines. Fulfilment of 
the suggested SE treatment algorithm is frequently hampered by failing recognition of 
SE at onset, also by professionals, which may increase the delays in consecutive parts 
of the treatment chain. Delays seem to be more significant determinants of SE 
duration than previously established outcome predictors. Additionally, various long 
delays in the treatment (second- and third-stage medication, diagnostic and tertiary 
hospital delays) increase the risk of mortality and poor functional outcome at hospital 
discharge and since the predictive cut-off point of these delays lies under 2,5 hours, 
the focus of protocol streamlining should be in the pre-hospital phase of the 
treatment. However, none of the delays are independent risk factors for poor 
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outcome, which reflects the dynamism of SE, but also demonstrates that every step of 
the treatment chain needs to be optimized.  
 
In conclusion, we propose that generation of simplified criteria for suspicion of an 
imminent SE and streamlining pre-hospital treatment chain are advocated. We suggest 
amendments to the protocol, such as triaging suspected SE patients with highest 
priority, recruiting physician-based EMS units upon primary alarm, administration of 
second-stage medication out-of-hospital and transportation of SE patients exclusively 
to hospitals with neurological expertise. Also, improvement of diagnostic possibilities 
on emergency site should be considered.  
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1 REVIEW OF THE LITERATURE 
1.1 Status epilepticus 
Status epilepticus (SE) is the most extreme form of an epileptic seizure. It is 
considered to be a life-threatening neurological emergency situation, which 
requires immediate treatment actions to cease the excessive electric activity in 
the brain. Even when treated with the best medical practices, it may result in 
substantial morbidity and mortality. 4 - 16 % of the epileptic patients experience 
SE during their lives1. 
1.1.1 Definition 
Already in 1867 Trousseau perceived that “in SE, when convulsive condition is 
almost continuous, something special takes place which requires an explanation”.  
In 1904 SE was defined as seizures occurring so frequently that “coma and 
exhaustion are continuous between the seizures”2. SE was included in the 
classification of seizures by the International League Against Epilepsy (ILAE) in 
1970. It was defined as a “seizure that persists for a sufficient length of time or is 
repeated frequently enough to produce a fixed and enduring condition”3. Over the 
following few decades animal studies demonstrated that continuous seizure 
lasting over 30 minutes may result in permanent neuronal damage4,5. In the early 
1990’s the most commonly used criterion for duration of seizures qualifying as SE 
was 30 minutes6-8. For decades the definition of SE was: 1) continuous seizure 
activity lasting over 30 minutes, or 2) two or more sequential seizures without full 
recovery of consciousness between seizures. That definition was easy to use, but 
since its theoretical grounds became questionable, in 1999 a new operational 
definition based on seizure duration over 5 minutes was proposed for time limit 
of SE9. Clinical data showing that spontaneous cessation of generalized convulsive 
seizures is unlikely after 5 minutes of convulsion10,11, and increased understanding 
of the pathophysiology of SE necessitated reformed definition and classification of 
SE, which was published in 201512.  
 
According to the current definition12, “SE is a condition resulting either from the 
failure of the mechanisms responsible for seizure termination or from the 
initiation of mechanisms which lead to abnormally prolonged seizures (after time 
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point t1). It is a condition that can have long-term consequences (after time point 
t2), including neuronal death, neuronal injury, and alteration of neuronal networks, 
depending on the type and duration of seizures”. Beyond the time point t1, the 
seizure should be regarded as “continuous seizure activity” and time point t2 
refers to the time after which ongoing seizure activity may result in long-term 
consequences. For convulsive (tonic-clonic) SE the best estimates for t1 and t2, 
based on animal experiments and clinical research, are 5 and 30 minutes, 
respectively. For other types of SE, time points remain undetermined due to lack 
of scientific evidence. 
1.1.2 Classification and clinical manifestation 
In the classification of SE, the purpose of the diagnostic axes is to provide a 
framework for clinical diagnosis, investigations and therapeutic approaches3,13. In 
the first classification (ILAE 1970)3 the axes included: (I) clinical seizure type, (II) 
electroencephalographic ictal and interictal expression, (III) anatomic substrate, 
(IV) etiology and (V) age. In 198114 in the revised classification axes were reduced 
to (I) seizure type and (II) EEG expression.  
 
Newly revised diagnostic classification system of SE12 includes four axes: (I) 
semiology, (II) etiology, (III) eletroencephalography (EEG) correlates, and (IV) age. 
Semiology contains two main taxonomic criteria: 1) presence or absence of 
prominent motor symptoms, 2) degree of impaired consciousness. Etiology is 
divided into two categories: 1) Known etiology (former symptomatic) and 2) 
Unknown etiology (including former cryptogenic). EEG correlates are denoted by 
the descriptors of EEG: name of pattern, morphology, location, time-related 
features, modulation, and effect of intervention. Age is divided into neonatal 
period, infancy, childhood, adolescence and adulthood (>12 to 59 years), and 
elderly age (≥60 years).  
 
According to the semiological criteria, the main types of SE can be divided into 
generalized convulsive SE (GCSE) (prominent motor manifestation with impaired 
consciousness), focal convulsive SE (focal CSE) (prominent motor manifestation with 
normal or slightly altered mental status), generalized non-convulsive SE (NCSE) 
(impaired consciousness without prominent motor manifestation) and focal NCSE 
(normal or slightly altered mental status without prominent motor manifestations). 
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1.1.3 Refractoriness 
Status epilepticus in considered refractory (RSE) to treatment if the seizure 
continues after treatment with first- and second-stage medications and the 
patient needs anesthetic (third-stage) treatment in the intensive care unit 
(ICU)15,16.  
 
The term super-refractory status epilepticus (SRSE) was introduced by Simon 
Shorvon in Third London-Innsbruck Colloquium on Status Epilepticus in 201117. 
SRSE is defined as status epilepticus that continues or recurs 24 h or more after 
the onset of anesthetic treatment, including those cases that recur on the 
reduction or withdrawal of anesthesia15.  
1.1.4 Epidemiology 
The incidence of SE ranges from 20 to 41 per 100 000 per year in large population- 
based epidemiological studies in USA18,19. European studies show somewhat lower 
overall annual incidence of 10 to 16 per 100 00020-22. SE occurs at all ages, but is 
most common in early childhood and among elderly19,20,22. Gender distribution 
varies in different studies, but appears mostly equal19. GCSE is the most common 
subtype of SE19, NCSE contributing to 11% of all cases and CSE to 89%23.  
In various retrospective studies 12% to 43% of all SE cases are refractory to 
treatment and 10% to 15% are super-refractory 15,24-28. Population based incidence 
rates of RSE are 3.4 – 5.2/100 000 and those of SRSE 0.7 – 3.0/100 00029,30. 
1.1.5 Etiology 
Etiologies of SE are numerous6,31,32. According to the recent ILAE Task Force on 
classification of status epilepticus12, etiologies are divided into Known (i.e. 
symptomatic) and Unknown (i.e. cryptogenic) categories. This categorization is 
consistent with the concept of the ILAE Commission for Classification proposal in 
201033. Known etiologies are subdivided into categories based on their temporal 
relationship: acute, remote and progressive. Also SE in defined electroclinical 
syndromes is notified in one subcategory.  
Acute etiologies include acute neurological disorders, such as stroke, head trauma, 
CNS infections e.g. encephalitis, intracranial hemorrhage or systemic disorders, 
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such as withdrawal or low levels of AEDs, electrolyte disturbances, abrupt alcohol 
or drug withdrawal, intoxication, anoxia. Remote symptomatic category includes 
etiologies that have caused prior insult in the brain (e.g. post-traumatic, post-
encephalitic, post-stroke) and progressive category is comprised of progressive 
neurological disorders (e.g. intracranial tumors, neurodegenerative diseases and 
PMEs)12.  
 
Among adults 43-81% of SE episodes occur in patients with previously diagnosed 
epilepsy18,19,21,34. Inappropriate AED treatment is the acute cause of SE in 22% - 34% 
of the cases19,24,26,32,35-38. In patients with previous seizures the percentage might 
be even higher, up to 53%38. Alcohol withdrawal or intoxication is the cause of SE 
in 8-24% of the cases19,26,35-38. Cardiovascular diseases and strokes comprise 4 - 23% 
of the SE etiologies19,24,26,35-38. CNS infections and intracranial tumors account for 
4 – 8% 26,35,38 and 4 – 6%24,26,35,37,38 of the etiologies, respectively. In 4 – 15% of the 
cases SE results from metabolic disorders19,26,35,37,38. The etiology remains 
unknown for 5 – 15% of the cases21,26,38. Among pediatric patients the most 
common identifiable causes are fever and infection31,39. 
1.1.6 Pathophysiology 
Normal epileptic seizures last only for a few minutes10,11 due to several biological 
processes that lead to seizure termination. These mechanisms include increased 
GABAergic drive, neurotransmitter depletion, ATP depletion, ionic changes, 
acidosis, release of adenosine and peptides40, and increased activity of pro-seizure 
processes (breakdown of the blood-brain barrier, inflammation, increased 
expression of pro-epileptogenic peptides41,42). Their failure may promote status 
epilepticus. Also, failure to increase spatial and temporal synchronization43 and to 
cross the critical transition from an ictal to a post-ictal state44 further induce 
progression of SE.  
 
A recent review of the pathophysiology of SE pointed out that the whole chain of 
events in the progression of SE could be seen as a failure of processes that “push” 
the seizure towards the post-ictal state45. Furthermore, the existence of SRSE 
could be seen as an indicator, that sometimes a stable post-ictal state no longer 
exists and even after anesthetic treatment the ictal state recurs. Two different 
processes were proposed to explain this: 1) an ongoing pathological process (e.g. 
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infection, autoimmune disease) driving brain back to ictal state, 2) underlying 
pathology or SE itself inducing changes in the brain that make post-ictal state 
intrinsically unstable45. Reinforcing stabilization processes of post-ictal state with 
AED treatment (i.e. inhibitory GABAergic medication) is necessary to terminate 
the SE. Most animal models show that experimentally induced SE could be 
suppressed or terminated with drugs46. 
 
Animal models have shown that the longer the SE continues, the more difficult it 
is to treat47-49. Experimental evidence suggests that when seizure activity is 
stimulated for over 30 minutes, the inhibitory mechanisms exhaust and seizure-
promoting processes strengthen, leading to self-sustaining SE, although the 
stimulation has stopped50,51. SE seems to activate several growth and 
transcriptional factors that regulate gene expression of GABAA-receptor in a way 
pertinent to lowering seizure threshold52. Prolongation of SE over 30 minutes 
induces synaptic GABAA-receptor trafficking and internalization from the cell 
surface, resulting in loss of inhibition and resistance to pharmacological 
treatment49,53,54. At the same time, NMDA receptor expression increases in 
excitatory cells amplifying the electric activity55. Additionally, expression of pre-
synaptic adenosine A1 receptor and GABAb receptor is decreased50,56. AMPA 
receptors lose their GluA2 subunit, which increases calcium permeability and 
contributes to accumulation of calcium, and possibly leads to neuronal death57. 
Furthermore, aberrant expression of drug transporter proteins may promote 
increased resistance to AEDs58. 
 
These modulatory changes in receptor and protein expression are of great 
importance when considering treatment options for SE, especially refractory SE. 
1.2 Outcome 
Short-term outcome of SE has been defined in most of the studies based on 
mortality and functional outcome at hospital discharge or in 30 days. Evaluation 
of the functional outcome has been performed using clinical scales: Modified 
Rankin Scale (mRS) and Glasgow Outcome Scale (GOS) or by evaluating the 
condition relative to baseline prior the episode of SE. The number of studies 
concerning long-term outcome is low, but those published have evaluated long-
term outcome in terms of mortality from one year up to median 12 years59-62.  
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1.2.1 Mortality 
Short-term mortality rates differ markedly depending on the underlying etiologies, 
patient’s age, refractoriness and seizure duration. Therefore, reported overall 
mortality ranges from 1,9% to 40%19-21,28,36,38,63,64. Mortality has decreased in the 
21st century65,66, possibly due to improved facilities and treatment options. SE 
with anoxic etiologies is related to high mortality. Anoxia is commonly excluded 
from SE studies as a devastating entity with poor prognosis and markedly different 
treatment options and protocols compared to the standard SE treatment 
protocols. 
 
Long-term mortality rate is markedly higher among SE patients compared to 
general population. 25% of ICU-treated RSE patients died within one year, despite 
the relatively low in-hospital mortality of 7.4%67. Reported cumulative mortality 
at 10 years among 30-day survivors after the incident SE episode was 43%61.  The 
data on long-term mortality are scarce and indisputable determinants of mortality 
remain still unclear. Plausible candidates are refractoriness, etiology, pre-existing 
characteristics of the patient and age.  
1.2.2 Morbidity 
Status epilepticus bears a considerable risk for increased morbidity after the SE 
episode68,69. Prolonged RSE itself and its treatments may result in general brain 
atrophy70, and in neuronal loss and progressive atrophy in the hippocampal area 
5,71,72 due to neuronal cell necrosis, gliosis and network reorganizations. 
Hippocampus seems to be extremely vulnerable to prolonged seizures73. Those 
who survive SE may have cognitive and neurological deficits and increased risk of 
developing chronic epilepsy74. Acute symptomatic SE has a three-fold risk of 
generating chronic epilepsy when compared to acute symptomatic seizures74. 
Febrile SE (FSE) in children is associated with subsequent temporal lobe epilepsy 
(TLE) and hippocampal sclerosis75-78. This is presumable considering the results 
from animal studies, in which prolonged hyperthermic seizures of over 60 minutes 
in immature brain cause TLE79. In human patients, the most common long-term 
complications incorporate chronic epilepsy (20-40%), encephalopathy (6-15%) and 
neurological deficits (9-11%)80.  
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Prolonged hospital admission, acute symptomatic etiology and prolonged seizure 
are associated with morbidity and decline in GOS at hospital discharge81. After 
ICU-treated RSE 23.8% of the patients were discharged to home, 47.4% to primary 
healthcare wards and 21% to specialist care facilities67. The discharge destination 
seems to predict long-term outcome, the 1-year mortality being lowest among 
patients discharged to home67. 
1.2.3 Factors related to outcome  
SE is an exceedingly dynamic process and several factors during the process have 
been proposed to influence the patients’ outcome, e.g. etiology, patient’s age, 
depth of coma at onset, structural brain lesion, EEG findings during/after SE and 
duration of SE19,25,36,38,61,65,81-83. Influencing factors can be divided into three 
categories, 1) patient’s pre-existing characteristics, 2) factors related to the current 
SE episode and 3) treatment and complications. Most of the influencing factors 
are pre-existing and cannot be affected, therefore, treatment and complications 
should be in the focus when aiming to improve SE patients’ outcome. 
1) Patient’s pre-existing characteristics 
Mortality of SE increases with age. Pediatric patients have the lowest mortality 
rate of 0-5%6,19,31 and elderly patients have the highest, even up to 76%61. In an 
epidemiologic study from Switzerland, the overall mortality during the hospital 
admission was 7.6% including all age groups. Mortality among adolescent and 
adult patients (15-59 years) was 15.4% and among the oldest (>60 years) 53.9%21. 
In the literature, old age, defined in most studies as the age over 65 years, 
correlates with worse outcome18,23,32,36,63,81,84-88. Still, the significance of age may 
partly be based on pediatric studies, in which age has been the major determinant 
of prognosis, in contrast to adult SE65,85. Higher mortality of elderly SE patients can 
be related to more frequent appearance of treatment complications and lower 
compensatory mechanisms89,90. 
 
The impact of the gender on SE’s outcome is relatively unclear. Some reports 
suggest that gender does not have significant effect on outcome36,84, albeit in 
some studies female gender seems protective91,92, and in others even predicts 
higher mortality93.  
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Pre-existing co-morbidities are related to the outcome after SE. Multiple medical 
problems, e.g. diabetes mellitus and extra-cranial malignancy at the onset of SE 
worsen the prognosis94,95. Charlson Comorbidity Index (CCI)96 is one of the 
available co-morbidity scores and it is the most reliable score for predicting 
outcome in various medical problems97. CCI is incorporated in Epidemiology-Based 
Mortality Score in Status Epilepticus - (EMSE) score98 due to its predictive value for 
poor outcome and mortality among SE patients93,98. Co-morbidities have been 
estimated to affect the outcome of SE relatively marginally, whereas age and 
etiology appear more robust and widely applicable predictors99.  
 
Pre-morbid functional status is related to outcome. Dependence in activities of 
daily living (ADL) and high mRS score (mRS 4-5) prior to SE are associated with high 
mortality67,95,100. Pre-morbid mRS has been recently incorporated in one of the SE 
prognostic scores, Modified Status Epilepticus Severity Score (mSTESS)100. 
Although functional capacity prior to SE seems important in relation to prognosis, 
it has been only rarely reported95,100-103. According to these reports, the pre-
morbid condition varies substantially between studies, the proportion of patients 
with poor functional status (mRS 4-5) ranging from 0% to 45%100,102,103. This may 
reflect differences in treatment protocols and patient selection between countries 
and hospitals, which make comparison of different studies cumbersome. 
2) Factors related to the current SE episode 
Several studies suggest that underlying etiology of SE may the primary 
determinant of prognosis89,94,104,106. Some investigators believe that this might be 
true especially when SE is treated aggressively, but not necessarily when the 
treatment has been less than optimal106.  
Previously diagnosed epilepsy has been related to improved survival after 
SE19,34,36,92,94,104,107. The SE episodes in epilepsy-related cases are commonly 
thought to be easier to treat, and in most studies their outcome is found to be 
better than that of patients presenting SE with acute symptomatic 
etiologies84,92,104. The presence or absence of previous seizures has been used as 
a surrogate marker for etiologies (i.e. absence implicating acute symptomatic 
etiology) in Status Epilepticus Severity Score (STESS)84. Low blood levels of 
antiepileptic drugs (AED) among epileptic patients and inappropriate consumption 
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of alcohol are related to low mortality19,32,36, whereas anoxia and acute 
symptomatic etiologies predict poor outcome and high mortality23,36,81,91,104,105,107. 
Progressive etiologies (e.g. intracranial tumors) and focal neurological symptoms 
are also associated with poor outcome87,105. Also, the finding in the neuroimaging 
seems to relate to prognosis, so that immaculate imaging findings are associated 
with better outcome, whereas bilateral abnormalities associate with worse 
outcome108,109. 
 
SE type and level of consciousness at SE onset are both incorporated into 
outcome score STESS because of their relation to the outcome 84,104. Patients with 
focal SE are more likely to survive the SE than patients with generalized SE, and 
coma at SE onset predicts worse outcome than slightly altered or non-altered 
mental status at onset104. Both convulsive SE and non-convulsive comatose SE are 
related to high mortality84.  
 
Also, the course of SE, whether it is continuous or intermittent, may affect the 
outcome. In some studies, continuous SE/seizure activity has been associated with 
increased mortality23 and regarded more dangerous than intermittent course110. 
On the other hand in a community-onset pediatric study that CSE cases with an 
intermittent course had longer SE duration, longer delay in calling the emergency 
medical service (EMS) and longer delay in arriving at the accident site and 
emergency department than cases with continuous course, possibly reflecting 
under-recognition of intermittent CSE as a serious emergency82. However, in 
another pediatric study the initial treatment delay remained equal in both types 
of SE course111. 
 
Refractoriness is associated with higher mortality23,86 and functional 
deterioration24,28. Mortality ranges among non-RSE cases from 8% to 12.6%25,30,86, 
whereas among RSE cases it has been reported to be even threefold (16% to 
39%)24,25,27,30,86,113. Patients’ condition after SE at hospital discharge return to 
baseline in 50% of non-RSE cases, whereas baseline condition is attained only in 
every third RSE patient25. Long-term mortality in SRSE is two times higher than in 
RSE29. Higher mortality among refractory cases treated in ICU might be related to 
the fact that most deaths among SE patients are caused by ICU complications94,114. 
 
Duration of SE has been reported to be one of the main predictors of 
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outcome23,81,87,89,115. Differences in defining the duration make the comparison of 
studies really challenging. Definition regarding the onset of SE seems to vary 
between studies from the real onset time to the time point of diagnosis95,116,117. 
Also, the exact endpoint of SE is conceptually problematic and varies in the few 
previous studies that have clearly defined the endpoint. Rantsch et al. defined the 
end point as the end of the clinical convulsion90. However, absence of clinical 
seizures as the only marker for the cessation of SE seems insufficient, since even 
48% of the seizures may continue as electrographic SE118. A few studies have used 
a combination of last clinical seizure and last continuous electrografic seizure as 
the criteria without any specific time frames25,104. Mayer et al. used additional time 
frame criteria, requiring the patient to be seizure free for at least 72h after the last 
clinical or electrographic seizure24. Return of consciousness or return to baseline 
mental status is rarely used, but could be the only clinically reliable marker for the 
end of GCSE. Defining the exact time attributes regarding the duration of SE is of 
great importance in the future study protocols. 
 
Median duration of SE varies from 2.5 to 48 h in previous studies24,38,104,119. Even 
25–30 % of the seizures prolong over 24 h 18,21. In a pediatric study, every minute 
of ongoing seizure elevated the risk for seizure prolongation over 60 minutes by 
five percent82. Prolonged duration of SE weakens the treatment response81 and 
may increase the number of complications due to longer treatment period. Still, 
even among prolonged refractory SE cases meaningful functional and cognitive 
recovery is possible104,120. 
 
Long duration of SE is related to poor outcome87,89,103,104. The longer the duration 
of SE, the worse the prognosis, particularly after 1-2 h of continuous seizures, 
although the relation may not exist, if the duration exceeds 10 hours65. Different 
predictive duration cut-offs have been proposed in various studies ranging from 
30 minutes to several days23,36,65,86,89,103,121. This variety might reflect problems in 
defining the onset and end point of SE, leaving the critical maximum duration 
undetermined. Nevertheless, permanent brain damage in SE is time dependent, 
and seizure duration is the only prognostic factor that can be affected by rapid 
treatment 87. 
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3) Treatment and complication 
Delayed treatment of SE has been associated with poor prognosis38,86,122 and 
suboptimal or delayed response to medication123. Although there are reports that 
question the delays’ relation to prognosis84,90,113,124,125, it is evident that prolonged 
duration of SE associates with poor outcome 87,89,103,104. While treatment delays 
correlate with longer duration of SE111 and treatment protocol adherence 
improves patients’ outcome116,126,127, delays cannot be ignored in the evaluation 
of prognostic factors of SE. Treatment of SE consists of several components and 
delays of those components and their effect on prognosis of SE is addressed more 
detailed in the Delays in the treatment-section later in this chapter.  
 
Adherence to treatment protocols, quality of treatment, proper drug sequence 
and management within the suggested timeframes seem to have a significant 
impact on the prognosis of SE. Existing literature and experts’ opinions strongly 
emphasize the importance of the quality of treatment116,126-129, although a recently 
published study suggested that treatment latency and adherence to protocol are 
not related to outcome of SE130. Additionally, delayed third-line treatment >1 day 
has been associated with increased recovery compared to delay <1 day131. This 
discrepancy may reflect the finding that delays in the treatment and compliance 
with suggested protocols are far from optimal, regarding both adults and 
children34,111,116. Also, heterogeneity of etiologies, SE severity and refractoriness 
may complicate the interpretation of the results.   
 
Evidence of the significance of intravenous anesthetic drug (IVAD)-treatment 
itself on the prognosis is contradictory; some studies consider it harmful for the 
patients117,132,133, while opposite conclusions suggest that the poor prognosis of 
IVAD treated patients is associated rather with more severe etiology of SE, 
refractoriness and increased number of complications, than with IVAD treatment 
itself100,103,134-136. Anaesthetic treatment is discussed more detailed in Treatment 
section later in this chapter.  
 
Systemic complications in the treatment of SE are commonly encountered and 
even 85% of the SE patients present failure of at least one organ system during the 
SE episode23. Complications may involve every organ system. Risk of complications 
increases due to prolongation of SE and treatment in ICU38,81,137,138. Conversely, 
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complications increase the risk of refractoriness137 and prolong hospitalization95. 
A few studies report that mortality in SE might be related to systemic 
complications even in 12 - 50% of the cases23,100,101,138. Complications, such as 
infection102,103,137, cardiac injury, arrhythmias, vasopressor use101,102,132,139,140 and 
mechanical ventilation102,132, have been associated with mortality and poor 
outcome. In the latest Colloquium on status epilepticus in Salzburg 2017 a tool to 
estimate the total burden of complications was introduced. The study suggested 
that complications in more than 3 organ systems during the course of SE were 
related to mortality and poor functional outcome141.  
1.2.4 Outcome scores 
During the last decade four outcome scores have emerged: STESS84,88, mSTESS100, 
EMSE98 and END-IT109. These scores include variables that are related to outcome 
(Table 1.-4.). STESS and EMSE have been internally and externally validated. Most 
of the above-mentioned variables associated with prognosis are incorporated in 
the scores, however none of the scores take into account delays in the treatment, 
nor the duration of SE. 
 Outcome scores of SE: STESS 
 
STESS
RELATIVE FACTOR CATEGORIES POINTS
Consciousness Alert or somnolent/confused 0
Stuporous or comatose 1
Worst seizure type Simple-/complex-partial, absence, myoclonic 0
Generalized-convulsive 1
Non-convulsive in coma 2
Age < 65 years 0
≥ 65 years 2
History of previous seizures Yes 0
No or unknown 1
TOTAL 0-6
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 Outcome scores of SE: mSTESS 
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 Outcome scores of SE: EMSE 
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 Outcome scores of SE: END-IT 
 
STESS is a tool for systematic evaluation of the outcome of SE patients and may be 
used to recognize patients, who need aggressive treatment84,88. In the original 
study, STESS points 0-2 and 3-6 predicted good and poor outcome, respectively. 
However, the cutoff-point for poor outcome is a subject of debate62,90,142,143,144. 
mSTESS is a modification of the original STESS incorporating evaluation of pre-
morbid condition. mSTESS >4 predicts fatal outcome with overall accuracy 
considerably higher than that of STESS≥3100. EMSE is an explorative, hypothesis 
generated, epidemiology-based score, where score points for each parameter 
were derived from previously published mortality rates. EMSE, with cut-off 64 
points, yielded the best results in predicting mortality. Studies comparing STESS 
and EMSE have shown some superiority of EMSE in predicting mortality and 
functional outcome145, however EMSE may lack utility in the emergency room in 
the early phases of SE treatment. END-IT was created in China, and the baseline 
population differed markedly from the Western population in age distribution and 
in etiologies. Consequently, it might not be directly applicable in Western 
countries109.  
END-IT
RELATIVE FACTOR CATEGORIES POINTS
Encephalitis Yes 1
No 0
NCSE Yes 1
No 0
Diazepam resistance Yes 1
No 0
Image Bilateral lesions/ diffuse cerebral edema 2
Unilateral lesions 1
No responsible lesion 0
Tracheal intubation Yes 1
No 0
TOTAL 0-6
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1.3 Treatment 
1.3.1 Treatment guidelines and protocols 
The first international guideline of the management of convulsive SE was 
published in 19936. It was consensus-based and provided physicians with 
consistent and rational approach. During the last decade a few updated guidelines 
have emerged aiming to provide an evidence-based guideline146-148. Protocols 
facilitating urgent treatment have been supported by experts149,150. The latest 
update was published in 2016, focusing on convulsive SE in adults and children151. 
The guideline proposed an updated treatment algorithm for convulsive SE, based 
on Level A and B evidence concerning the recommended medication in the early 
stages of SE. Recommendations for the treatment of RSE or SRSE have been 
addressed in the earlier guidelines and reviews15,147,148.  
Fig 1. Proposed treatment algorithm for status epilepticus. 
Reprint permission from AES. 
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Staged treatment approach has been recommended since the first guideline in 
19936,146,147,149,152, but the increased understanding of the pathophysiology has led 
us to recognize that “time is brain” also in SE, although there is no evidence-based 
timeframe for treatment. Current guidelines suggest aggressive early treatment 
with the tendency towards shortening the recommended timeframes of 
treatment15,147,148,151. 
 
Treatment of SE is an extremely dynamic process with diagnostic challenges, 
several treatment stages, and potential misinterpretations over the whole 
management process. Therefore, streamlining the treatment protocol is needed. 
Although treatment of acute stroke is more straightforward than that of SE, 
approaches used in stroke treatment chain streamlining could be implemented to 
optimize the SE management. Changes in the management protocol, after 
evaluation of the crucial delays in the treatment chain of stroke thrombolysis 
candidates, have reduced the intra-hospital delay (door-to-needle-time) from 
median 105 minutes to 20 minutes153.   
1.3.2 Treatment 
Staged treatment protocols guide the treatment in the early phases of SE, while 
there are no evidence-based guidelines for the treatment of RSE and SRSE. 
Treatment of RSE is based on anesthetic treatment and is covered as the third-
stage treatment section in this literature review. Treatment of SRSE leans on 
experts’ opinions, and anesthetics (propofol, barbiturates, midazolam, ketamine, 
inhalation anesthetics) with up to 3 different AEDs in large doses are 
recommended. Treatment of the etiology of SRSE is important and therefore also 
immunotherapies (high dose prednisolone, iv. immunoglobuline, 
cyclophosphamide, rituximab), magnesium-infusions, hypothermia, ketogenic 
diet and stimulators (VNS, DBS) should be considered15,45,154. Newest treatment 
approaches include neurosteroids (extrasynaptic GABAa receptor inhibition)155-157, 
NMDA inhibitors and calcineurin antagonists158,159. 
1.3.3 Delays in the treatment 
No systematic studies on the delays in the clinical course of SE have been 
published prior or during this study. Most of the studies regarding delays in the 
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treatment of SE concentrate on treatment delay, which reflects a limited part of 
the whole process. Comprehensive evaluation of the management process 
requires recognition and assessment of all individual delay components.  
Treatment delays 
A recent review of the treatment delays and treatment adherence in SE found only 
17 publications considering treatment delays since year 2000, two of which are 
part of this thesis. All of them issued delays to initial treatment, but only five 
publications issued delays to second- and third-stage medications160. This review 
demonstrated pervasive delays in the treatment of SE. 
 
The effect of treatment delay on outcome in SE is controversial and subject to 
debate. Most studies, as seen in the recent review160, have focused only on the 
relation between first-stage medication and outcome. Several studies show that 
the treatment delay has a clear impact on the prognosis; the longer the delay, the 
worse the outcome38,86,122,161, and some suggest that, besides the etiology, the 
treatment delay plays an important role89,162,163. Opposite results suggest that a 
long treatment delay does not correlate with increased mortality84,90,94,125, and 
consequently the prognosis of SE is mainly determined by its biological 
background113 and affected by its refractoriness90. It is also possible that treatment 
delay is critical for extremely severe SE episodes, although not for all types of SE125. 
Clarification of this matter is warranted. 
 
1) First-stage treatment 
 
There are several requirements for the effective first-stage treatment. 
 
The most effective medication should be used. Intravenous benzodiazepines 
(lorazepam, diazepam, clonazepam), intramuscular midazolam and rectal 
diazepam are approved as efficacious and essentially equivalent first-stage 
medications with clear superiority to placebo162,164-167. Earlier, rectal diazepam gel 
has been used as an alternative for intravenous administration and usage in pre-
hospital environment, e.g. at home, has been advised as a measure to shorten the 
treatment delay168. Development of preparations for other administration routes 
(buccal, intranasal, intramuscular) has enabled more rapid and socially more 
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acceptable administration of medications164,167. Especially after RAMPART study162, 
the usage of intramuscular midazolam has increased169. Although a few studies on 
North American patients report that non-benzodiazepine initial therapy was 
applied in only up to 7% of convulsion cases127,170, a worldwide survey reports a 
substantially higher proportion of 67%131. 
 
Adequate dosing of the medications is essential. Under-dosing benzodiazepines 
might be falsely interpreted as benzodiazepine-resistant SE and may lead to 
unnecessary acceleration of the treatment to higher stages171. Over-treatment 
with benzodiazepines has been associated with increased need for intubation and 
prolonged hospital stay172. 22% - 90% of the patients have been reported to 
receive suboptimal weight-based dosing76,170,173,174. Pre-filled medication 
dispensers might be influential for adequate dosing during the initial treatment. 
Overall pre-hospital benzodiazepine medication has been considered safe and 
efficient with the benefit of the treatment exceeding the risks of complications, 
such as respiratory depression82,116,165,175,176.  
 
The medication should be administered without delay. Although the suggested 
timeframe is not evidence-based, administration should take place within 5 - 10 
minutes after seizure onset148,151,177,178. It has even been suggested that rapid 
administration per se is probably more important than the actual agent179. 
Adherence to initial treatment protocol has been reported to be the main factor 
associated with seizure termination116. Regardless of this, reported median 
treatment delays are far from optimal and range from 28 minutes to several 
hours38,76,86,90,111,116,123,129,161,168 among public onset SE cases. Only ICU onset cases 
have managed to meet the treatment delay requirements23 so that initial 
treatment delay in cases occurring in hospital is shorter than the of out-of-hospital 
onset cases111,126,128. In addition, only 31%-54% of the patients are initially treated 
out-of-hospital76,111,161,170, albeit pre-hospital treatment, especially pre-hospital 
diazepam among pediatric patients, has been associated with shorter duration of 
SE116,175 and pre-hospitally applied rectal medication lowers the incidence of 
prolonged convulsion82. Patient education and a clear seizure emergency plan are 
needed to reduce unnecessary delays168.  
 
It is crucial to interpret the response to medication correctly to be able to continue 
with the adequate treatment in the initially treatment-resistant cases with a high 
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risk of nascent SE. Caregivers treating patients with recurrent seizures should be 
advised to monitor the clinical response in order to recognize the need for 
immediate professional evaluation 181.  
 
2) Second-stage treatment 
 
Traditionally available intravenous medications are phosphenytoin and valproate 
and newer ones include levetiracetam and lacosamide. Proper evidence of any 
agents’ superiority is lacking182-185. Two studies propose that valproate and 
phosphenytoin are equal in efficacy185,186. In a few studies, phosphenytoin has 
been combined with traditional first-stage medication in out-of-hospital 
treatment116,187 and the combination might be efficient in 2/3 of the seizures122. 
Still, safety and storage issues of phosphenytoin restrict its use on site. There is 
some evidence that the use of newer AEDs in the treatment of SE may lower the 
chance of return to baseline condition at discharge and result in higher rate of 
refractoriness188,189, but a newly published randomized study suggested that 
levetiracetam controls status epilepticus with an efficacy comparable to that of 
phenytoin190. Therefore, there is an urgent need for the results from an ongoing 
randomized trial comparing phosphenytoin, valproate and levetiracetam in the 
treatment of established SE, ESETT191 and from the planned randomized pediatric 
trials ConSEPT and EcLIPSE comparing levetiracetam and phenytoin192,193. It is 
worth noting that in ESETT, patients are randomized according to the drug, but the 
delay in giving the agent is uncontrolled.  
 
Only a few studies report onset-to-second-stage medication delay. In those studies, 
median delay ranges from 69 to 105 minutes111,116. This is clearly longer than the 
guidelines’ suggestions to move to second-stage medication within 20 - 40 
minutes, if seizures persist after first-stage treatment148,151,177,178. Adherence to 
protocol and attempts to reduce delays is important, since in a prospective 
study116 patients receiving first long-acting AED according to the treatment 
protocol (fosphenytoin or lorazepam) were 19.9 times more likely to obtain seizure 
termination. 
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3) Anesthesia i.e. third-stage treatment 
 
According to the guidelines, the third-stage treatment, i.e. intravenous anesthetic 
drug (IVAD), includes treatment with propofol, thiopental (in USA rather 
pentobarbital) and/or midazolam147,148. Additionally, the use of ketamine is 
increasing. So far there are no studies showing superiority of any of the IVADs used, 
and the choice of agent does not seem to influence the outcome or 
mortality25,115,194. Using propofol bears a 10 % risk of life-threatening complication 
of propofol infusion syndrome (PRIS)195. On the other hand, propofol shortens the 
hospital stay and may improve the patient outcome, as compared with other 
anesthetics, possibly due to the short duration of action25. However, propofol does 
not significantly differ from other agents34,196, since all IVADs may induce serious 
adverse reactions, mainly hypotension and respiratory depression134.  
 
Treatment with IVADs is suggested to be monitored by EEG to demonstrate seizure 
suppression, or burst-suppression (BS) as the proper treatment response, but also 
suppression of all background activity has been proposed148,197. BS is suggested in 
the European guidelines147, while the American guideline states that EEG endpoint 
of treatment is controversial148. The evidence for the utility of BS as a treatment 
goal is scarce and the effect of BS on prognosis remains undetermined65. BS level 
has been advocated as the goal for SE treatment based on evidence, that the 
depth of EEG suppression (i.e. BS) correlates with favorable treatment 
response115,198. Still, its significance in predicting permanent absence of seizures, 
mortality, or clinical recovery has been questioned25,115,198. In a few studies the 
achievement of BS was not superior to epileptiform suppression with regard to 
mortality or functional outcome25,199. In turn, presence of BS, regardless of SE 
etiology or the medication administered, has been associated with grave 
prognosis85 and seizure control without suppression of electric activity to BS or 
isoelectric level is associated with good functional recovery102.  
 
Initiation of IVAD treatment in cases refractory to first- and second-stage 
treatment is recommended after 30 - 70 minutes of continuous seizure activity, 
especially in GCSE cases148,151,177,178. Reports on the delays in IVAD initiation and 
the effect of the delays on the outcome are nearly lacking. In a pediatric study, 
median delay in starting anesthesia was 180 min111 and in an adult study from 
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years 2001-2010, onset-to-anesthesia-delay was reported to be 1–2 h in 37 % of 
the cases and 2–24 h in 63 % of the cases34. Recent results from a global audit 
(2015), where only 16% of the patients are treated within 1 hour, show no real 
improvement131. It has been claimed that long delay in starting anaesthesia does 
not necessarily mean poor outcome94, but the evidence is scarce and requires 
further studies in the future. 
 
Maintenance of BS for at least 24 hours is recommended by the guideline147. This 
policy is well adapted, since circa 70% of the treating physicians aim at BS level for 
24-48 hours180, although there are no data indicating the duration of treatment 
sufficient to obtain permanent seizure termination148. In previous reports, the 
total anaesthesia time varies from median 21.5 hours to several days, depending 
on the severity and refractoriness of the SE34,102,112. The length of IVAD treatment 
is a subject of debate. Long anesthetic treatment has been associated with both 
poor102 and good94 outcome. It predisposes to increasing number of complications 
as the sedation time prolongs and in that way poor outcome may be in prospect. 
Also, sedation in general, especially in higher doses seems to be associated with a 
higher incidence of cognitive dysfunction200. However, multiple studies have 
shown that in etiologies other than anoxia the possibility of meaningful functional 
and cognitive recovery even after weeks of anesthetic treatment is possible. No 
clear duration of SE or number of failures in weaning the anesthetics can be 
defined to justify the case to be considered futile87,102,104,120,201.  
Pre-hospital delays 
Pre-hospital management of SE has been studied mainly with the focus on 
medication selection, safety, and efficacy of the treatment given  
out-of-hospital82,116,165,175,176. Other aspects in the pre-hospital period have raised 
less interest. Although there is no clear evidence of the effect of the delay in pre-
hospital initial treatment on patients outcome161, lack of pre-hospital treatment 
has been associated with prolongation of SE over 60 min among pediatric 
patients82. As mentioned above, administration of AEDs already out-of-hospital 
concerns only a minority of SE patients and therefore pre-hospital period could be 
seen as a missed opportunity for timely intervention, as speculated in a recent 
review160. 
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Delays in calling the ambulance and factors related to those delays have not been 
systematically studied among SE patients. Reported delays from onset to alarm 
are 12.5 to 30 minutes76,161, which are somewhat shorter than reported median 
delays among stroke-patients202,203. Comparison is inadequate, since reports on 
delays among SE patients are so scarce. Long delays in medical emergencies reflect 
wait-and-see-attitude among patients and caregivers, what seems to be difficult 
to change despite public education campaigns on emergencies like stroke203. 
Among stroke patients fear of disease and hospital and living alone were the main 
factors lengthening the alarm delay, whereas severe symptoms and moderate to 
high score (> 8) on NIH Stroke Scale (NIHSS) at onset, presence of family members 
or bystanders and female gender were associated with shorter delays202-204. 
Among SE patients, continuous convulsive seizures in SE could be comparable to 
high NIHSS-score in stroke as a marker for severity leading to accelerated 
operation. Indeed, this was seen in a pediatric study, where intermittent seizures 
triggered alarm call with longer delay than continuous seizures82.  
 
Reports on pre-hospital delay range from 30 minutes to 105 minutes among SE 
cases24,76,82,161,173,206,207. In a pediatric study on community-onset SE, intermittent 
course of SE onset was associated with longer delay in arriving at the accident site 
and emergency department than that in cases with continuous course, reflecting 
under-recognition of intermittent CSE82. Knowledge of other relating factors 
among SE patients is deficient. Stroke studies divide pre-hospital period to 
sections: onset-to-call time, on-scene time (OST) and transportation-to-hospital 
time. Onset-to-call time may account even for 20% of the total pre-hospital 
delay203 and delays depending on the patient were estimated to be the most 
significant ones208. Minimization of the OST is important especially in maladies, for 
which treatment is available only in hospital, e.g. thrombolysis in acute stroke. OST 
could be reduced by 10 % by EMS personnel in a prospective interventional study 
of stroke patients. Level of expertise of the ambulance crew seems essential for 
the OST, since higher expertise level decreases the need to consult physician via 
phone and consequently reduces OST209. However, increase in the number of 
personnel available on site did not markedly change OST210. Acute myocardial 
infarction studies show that the importance of the length of OST and the time 
spent on transportation decreases, if the treatment could have been started on 
site immediately after diagnostic procedures and managed through telemedicine 
consultation211. This approach could apply on SE patients. The most important 
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factors in stroke and cardiac infarction studies relating to pre-hospital delays 
constitute of early diagnosis on site210,212, usage of stroke as the specific dispatch 
code (in stroke studies) and triaging patients to highest priority203,208. In reducing 
pre-hospital delays, multiple strategies should be considered including education, 
symptom detection and prediction systems, pre-notification of hospital, physician 
staffed EMS units, telemedicine consultation and triaging patients directly to 
specialized hospitals202,215.  
 
Organization of EMS systems and treatment arrangements in hospital districts vary 
tremendously throughout the world and even within countries. There are very 
little, if any, studies comparing different systems and their effect on SE patients’ 
outcomes. Patients treated in urban versus rural area hospitals were compared 
relative to mortality, with significantly higher mortality in urban areas, where also 
the quality of global drug treatment was inferior126. Furthermore, a trend towards 
worse outcome in tertiary hospitals was found in a prospective cohort comparing 
outcome in patients treated in tertiary hospital versus regional hospital, although 
groups were equal in relation to age and SE severity (STESS)213. However, stroke 
patients gained benefit of being transported directly to adequately specialized 
hospital with a stroke-unit rather than to other, possibly nearest, lower-level 
hospital214. 
Diagnostic delays 
Early recognition of SE and a proper diagnosis without delay are of greatest 
importance. Missed or delayed diagnosis is associated with a higher likelihood of 
poor response to treatment and worse outcome176. Median diagnostic delay has 
been reported to be 45 minutes to 4 days95,116, the shortest delay consisting only 
of patients with GCSE in France, where emergency units routinely include a 
medical doctor116. The delays in different EMS settings and in other types of SE 
might be even longer. In a recent study, the diagnosis of NCSE was missed by EMS 
in over 60% of the cases, whereas CSE was recognized in all cases expect for those 
with transformation into subtle SE216. These findings call for rigorous education on 
the risks of SE and support the conclusion presented in previous studies that there 
is a need for simplified criteria for suspicion of an imminent SE116,168. This approach 
is supported by studies on cardiac infarction, demonstrating that pre-hospital 
diagnosis shortens the pre-hospital delay and reduces mortality211,212. 
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Availability of EEG is essential for diagnosis, especially among NCSE cases. In ICU 
only 20% of SE diagnosis were made before EEG217. Median delays in starting 
continuous EEG (cEEG)-recordings range from 195 min (from SE onset) to 16.7 
hours (from ICU admission)116,218. Delays in initiation of cEEG in cases with 
electrographic SE has been associated with high mortality218. Improved availability 
of EEG is warranted, and several alternative settings have been tested. Forehead 
EEG electrode set shows a sensitivity of 50% in detecting NCSE with no false 
positive cases219. A 5-minute eEEG recording was shown to expedite SE diagnosis 
without compromising reliability in ED220 and a 7-electrode montage led to quick 
and reliable seizure detection in ICU221. In the future, seizure detection, seizure 
prediction and closed-loop warning systems could be useful for epilepsy patients 
in better recognition of SE222. Availability of EEG in ambulance for diagnosing 
purposes would be comparable to ECG for diagnosing AMI and mobile CT-imaging 
units for diagnosing stroke202.  
Treatment response delays 
Evaluation of the treatment response has been performed mainly for duration of 
SE. As mentioned above, that parameter lacks uniform definition and therefore 
stepwise evaluation of the treatment response is advocated. 
 
End of the first seizure in SE period has been reported to occur 60–180 min after 
the SE onset23,116. The median delay from SE onset to the end of the last seizure 
i.e. clinical seizure freedom has been reported to be 2.4 h in non-RSE and 92 h in 
RSE cases27. Only two prospective studies have issued the delay from SE onset to 
BS. The median delay of BS with thiopental anesthesia was 11.5 h223, and the 
corresponding delay with propofol anesthesia was 6 h224. The effect of the BS delay 
on prognosis is unclear, but one study speculates that achievement of BS during 
the first 7 days during the SE treatment is associated with better prognosis of 
patients with prolonged refractory SE in one-year follow-up. The reason for this 
might be related to better treatment strategies with patients achieving BS or to a 
greater treatment resistance of patients not achieving BS101. No previous studies 
have reported on the delay in return of consciousness. However, the delay from 
onset to clinical recovery has been associated with mortality after 10 hours104. 
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2 AIMS OF THE STUDY 
 
1) To define and determine the length of delay components in the 
treatment of status epilepticus. (I) 
 
2) To detect the most important factors related to pre-hospital delays in 
the treatment. (II) 
 
3) To determine the delays and factors related to the duration of status 
epilepticus. (III) 
 
4) To study the effect of the delays in the treatment on the outcome of the 
patients at hospital discharge. (IV) 
 
5) To find the most important delay components in the treatment chain for 
status epilepticus treatment protocol streamlining. (I-IV) 
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3 MATERIAL AND METHODS 
3.1 Study design 
Fig 2. Structure of thesis. 
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This study consists of four parts, all examining the same retrospective patient 
cohort from Helsinki University Central Hospital (HUCH). The study material 
includes consecutive adult patients (over 16 years of age) diagnosed with SE (I-II) 
or with generalized convulsive SE (GCSE) (III-IV) and treated in the HUCH ED over 
a two-year-period from January 2002 till December 2003. The first two 
publications (I-II) comprise all types of SE. Since SE patients are a very 
heterogeneous group, the last two publications (III-IV) exclusively examine CGSE 
patients, which is the largest subgroup of SE patients.   
 
HUCH is a tertiary hospital in Southern Finland serving a population of 1.4 million. 
Emergency service in the hospital district is provided by one tertiary university 
hospital (HUCH) with neurological emergency service operating round the clock, 
seven regional hospitals, in which the ED is run by internists, neurological 
consultation being available during office hours, and several primary health care 
centres. The EMS system includes paramedic-, nurse-, and physician-based EMS 
units in either ambulance or helicopter. At the time of material collection second-
stage medication was not at disposal for EMS. In cases of benzodiazepine resistant 
SE, physician- and nurse-based EMS units may induce anesthesia and intubate the 
patient at emergency site, based on consultation of the physician on shift. 
Emergency calls are centralized in Finland and trained personnel selects the type 
of unit needed at emergency site. Physician – or nurse-based units are recruited 
in cases of suspected SE, whenever available. All rescue units in the HUCH area 
have been instructed to transport SE patients, independent in daily living, 
primarily to HUCH ED. 
3.2 Collection of material 
The patients were identified in the HUCH electronic patient database by the ICD-
10 code G41 (SE), either as a primary or a secondary ED discharge diagnosis, 
yielding a total of 87 patients. Patients not meeting the criteria of SE (I-II) or the 
criteria of GCSE (III-IV) were excluded from the analysis, despite having the SE or 
GCSE diagnosis in their records. This resulted in a total yield of 82 SE patients and 
70 GCSE patients.  
 
The data were collected from the original medical records on a preformatted 
standard form designed for this study. The records consisted of notes made by 
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nurses and doctors of EMS, health care centres, regional hospitals, HUCH ED, ICU 
or neurological ward. Ambiguous data were evaluated by the research team to 
obtain consensus on conflicting remarks. If the consensus concerning the original 
coding rules changed, the data in question were recollected and re-evaluated for 
all cases. The electronic database was created using MS Access for data recording. 
The patient identification information was removed before further analyses. Most 
of the data concerning the grouping variables were objective, however, the 
definitive patients’ group assignments were settled after the data collection.  
 
This study conforms to the Finnish legislation concerning medical research and the 
permission was granted by the HUCH Department of Neurology. 
3.3 SE definitions 
In this study established SE was defined as continuous seizures lasting over 30 
minutes, or as several recurrent seizures without returning consciousness, or 
occurrence of more than four seizures within any one hour irrespective of return 
of consciousness in between. The definition was based on the national and local 
guidelines and followed the operational definition of SE being used at the time of 
material collection. The present-day definition was still under preparation at that 
time.  
 
Patients having a convulsive seizure at any point of the SE period were considered 
as having CSE. Seizures with impaired consciousness, either primarily or 
secondarily, were considered as GSE and those with normal consciousness were 
considered as focal SE. Seizures lacking motor manifestations were considered as 
NCSE. The seizure description of individual patients was collected from original 
medical records and seizure classification was also based on EEG, when available. 
 
The onset of SE was defined as the beginning of the first seizure fulfilling the 
above-mentioned criteria for established SE or GCSE. No clear definition for the 
end of SE was found in the literature. Therefore, we applied a stepwise definition 
for cessation of SE or GCSE applying three separate parameters: BS, clinical seizure 
freedom and return of consciousness. BS refers to the beginning of the first BS 
sequence during the current episode. Clinical seizure freedom refers to the end of 
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the last clinical signs of seizure, and return of consciousness refers to the time 
point, when the patient could communicate meaningfully.   
 
Patients failing to respond to the first- or second- stage treatment were considered 
as having RSE. SE continuing or recurring 24 h or more after the onset of 
anesthesia was considered as SRSE. 
3.4 Validation of the study material 
The retrospective character of the material raised the need to evaluate the 
documentation of the time points for accuracy and availability.  
 
The data on delays were based on events with exact time points documented in 
the medical records, whenever possible. For events not accurately documented, 
clinically grounded estimation of the event time was based on time frames with 
exact documented time points at each end. 
 
For accuracy evaluation we developed an accuracy score (LWAS) based on a 
mathematical formula for weighted average. LWAS for each time parameter was 
calculated using the formula 
 
 
 
 
 
 
 
where: k = accuracy coefficient (1, 2, 3). xi = number of cases at the beginning of the time 
interval in question with accuracy coefficient i. yj = number of cases at the end of the time 
interval in question with accuracy coefficient j. 
 
LWAS ranges from 1 to 3. Score 1 indicates exact time in documentation, whereas 
scores 1–2 and 2–3 indicate accuracy of 0–5 or 5–30 min, respectively. Inaccurate 
time points were excluded from the analyses. LWAS refers to the deviation of the 
time parameters from the absolute accuracy in the medical records. 
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For the availability of the delay material included in the final analysis, we 
calculated Data availability (DA), which refers to the percentage of cases for which 
any data was available.  
 
In addition to inaccurate time points, missing events, e.g. no anesthesia, events 
happening during pre-status period, or events with unknown data were excluded 
from the final analysis. Detailed reasons for missing values were reported in each 
publication. 
3.5 Measures 
3.5.1 Delay parameters 
We determined and calculated several delay parameters. Delays in the treatment 
consisted of pre-hospital delays, diagnostic delays and treatment delays. 
Treatment response delays consisted of the length of the first seizure, delays in 
obtaining burst-suppression, achieving clinical seizure freedom and returning of 
consciousness. The three latter delay parameters denoting markers for cessation 
of SE. Periods in the treatment, such as HUCH admission were calculated. Various 
diagnostic procedures, treatment interventions or other relevant events 
documented in the medical records were also recorded. Delay parameters are 
presented in Table 5. 
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 Delay parameters used in studies I-IV. 
DELAYS IN THE TREATMENT STUDY STUDY STUDY STUDY
PRE-HOSPITAL DELAYS I II III IV
Onset-to-alarm x x x
Standard ambulance x
Physician staffed rescue unit x
Alarm-to-EMS x
Standard ambulance x
Physician staffed rescue unit x
Onset-to-first-ED x x x
EMS-arrival-to-first-ED x
Onset-to-tertiary-hospital (HUCH) x x x x
DIAGNOSTIC DELAYS
Onset-to-diagnosis x x x x
Clinical diagnosis x
Diagnosis based on EEG x
Onset-to-EEG x x
Diagnostic EEG x
Treatment response EEG x
Onset-to-EEG-monitoring x x
HUCH-ED-to-cEEG x
Anesthesia-to-cEEG x
HUCH-ED-to-etiological-investigation x
CT of the head x
MRI of the head x
Lumbar puncture x
Sign. laboratory finding x
TREATMENT DELAYS
Onset-to-initial-treatment x x x x
Onset-to-second-stage-medication x x x
Onset-to-anesthesia x x x x
TREATMENT RESPONSE DELAYS
Onset-to-first-convulsion-end x x
Onset-to-Burst-suppression x x x
Anesthesia -to-BS x
Duration of first BS x
Onset-to-seizure-freedom x x x
RSE/SRSE cases x
Non-RSE cases x
Total-convulsion-time (convulsive cases) x
Onset-to-consciousness x x x
Non-RSE cases x
PERIODS IN THE TREATMENT
x
Total-ICU-time x x
Total-anesthesia-time x x
HUCH-treatment-period x
Pre-status-period 
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Delay parameters were counted from the onset of SE/GCSE, if not stated otherwise. 
“Total time” (e.g. anesthesia) was calculated by adding up the length of each 
individual event (e.g. anesthesia sequence) during the SE period. “Period” was 
calculated from the onset till the end of the event despite interruptions in 
between.  
 
Onset-to-alarm refers to the primary alarm, i.e. the delay in calling the ambulance. 
In some cases several ambulance calls were made, but only the primary contact 
was calculated. The term First ED denotes to the ED in which the patient was 
treated for the first time during the SE/GCSE. Only the cases transported to the ED 
by EMS were calculated to the Onset-to-first-ED time. HUCH ED was exclusively 
considered as the Tertiary Hospital ED, and all other ED’s, regardless of the level 
or location were collectively grouped as other hospital ED. 
 
Initial treatment was defined as the first AED given, which was not necessarily first-
stage medication. First-stage medication included iv. or rectal diazepam or iv. 
lorazepam. The patient was considered to respond to the initial treatment, if the 
seizure stopped within 10 min after iv. administration or 20 min after rectal 
administration of the initial medication, with no other simultaneous medications. 
The second-stage medication was defined as first second-stage medication given, 
which included iv. phosphenytoin or valproate. The patient was considered to 
respond to the second-stage-medication, if SE resolved after second-stage-
medication without anaesthesia. The third-stage medication included anaesthesia 
with propofol, thiopental or midazolam and the start of the third-stage medication 
was defined as the time point of induction of anaesthesia (onset-to-anaesthesia). 
 
Seizures occurring no more than 48 h prior to SE onset and reported as relevant 
part of the process are referred to as the pre-status period. Onset-to-first-
convulsion-end refers to the time between the onset of GCSE and the end of the 
first clinical convulsion.  
3.5.2 Other parameters 
Parameters for grouping variables were defined in three categories: SE type-
related, patient-related, and SE episode-related. The parameters and their use in 
different publications are presented in Table 6. Considering the goal of the pre-
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hospital part of this thesis (II), the precondition for variables used in that 
publication was that they could be determined for each case based on the period 
before the patient was admitted to hospital, i.e., either unambiguous background 
information, visible clinical signs of epileptic seizure, or documented pre-hospital 
events.  
 
Seizures lasting clinically at least 30 min were defined continuous. All other types 
of seizures were considered intermittent. Only subjects with previously diagnosed 
epilepsy were considered as patients having epilepsy. For age as a grouping 
variable, 65 years was selected as the classification basis. Healthcare units 
included hospital EDs, in-patient departments in hospitals and healthcare centres, 
as well as nursing homes.  Events occurring prior to the first ED were considered 
as pre-hospital events. STESS (A16) was used for SE severity assessment.  
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 Grouping variables used in studies II-IV. 
PARAMETERS STUDY STUDY STUDY
SE TYPE RELATED II III IV
SE type 1 CSE x x x
NCSE
SE type 2 GSE x x x
Focal
Pre-status period Yes x x
No
SE onset Continuous x x
Intermittent
PATIENT RELATED
Epilepsy Yes x x
No
Age under 65 Yes x x
No
Living Home x
Home with someone else
Nursing home
SE EPISODE RELATED
Scene at SE onset Home x
Healthcare unit
Public place
SE onset at home, pt living alone Yes x
No
Initial treatment before EMS Yes x
No
Rectiol as initial treatment Yes x
No
Effect of the initial treatment Yes x x
No
Spontaneous cessation
First ED Tertiary hospital x
Other hospital
Pre-hospital diagnosis Yes x
No
Pre-hospital anesthesia Yes x
No
STESS 2 x
3
4
5
Refractoriness Non-RSE x
RSE
SRSE
OUTCOME 
Condition at discharge Worse x
Baseline
GOS at discharge ≤3 x
>3
Mortality at discharge Yes x
No
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3.5.3 Outcome parameters 
Mortality was calculated over the treatment period in HUCH. No post-discharge 
follow-up was performed in this study. Cessation of GCSE was determined with 
three parameters used as markers for cessation: BS, seizure freedom and return 
of consciousness. Outcome of the patients was defined based on functional 
outcome and mortality at hospital discharge. Functional outcome was assessed 
using Glasgow Outcome Scale (GOS 1-3 for bad outcome, GOS >3 for good 
outcome) and condition relative to baseline condition (worse-than-baseline vs. 
baseline) at hospital discharge. Functional outcome was considered good if the 
patient returned to his/her baseline condition and GOS at hospital discharge 
was >3. Outcome measures at hospital discharge were collected from the medical 
records. 
 
While processing the pre-hospital part of this study (II), some coding rules were 
sharpened regarding pre-hospital procedures of the treatment. They were more 
clearly defined to the above-mentioned form. This induced some incoherence in 
results between studies I and II, affecting delay parameters Onset-to-alarm, Alarm-
to-EMS, Onset-to-first-ED, EMS-arrival-to-first-ED, Onset-to-initial-treatment and 
grouping variables SE onset, Effect of the initial treatment and pre-hospital 
diagnosis. Changes to the results (study I) proved to be minimal and insignificant 
and the amended results according to renewed coding rules are presented in the 
results section in Table 8. and 9.  
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3.6 Statistical analysis 
The results are expressed as median (min-max)/mean (SD) and/or 
range/interquartile range (IQR) or as number of patients and percentage. 
Statistical significance was defined as p < 0.05 and two-tailed tests were used. 
Statistical analyses were executed using the SPSS software (versions 20.0 (I), 21.0 
(II), 22.0 (III), 24.0 (IV), SPSS, IBM Corp. USA). 
Study I 
Statistical significance of the differences in variables between independent 
samples was tested with the non-parametric Wilcoxon-Mann-Whitney test. 
Differences in categorical variables were examined using Chi-square test.  
Study II 
The Mann–Whitney and the Kruskal–Wallis tests were used to find out differences 
in the univariate analysis between the patient groups. The Dunn’s test was used 
in post hoc comparisons. Multivariate analysis was performed with generalized 
linear modelling. Bootstrap resampling (1000 samples) was used to calculate the 
bias corrected percentile confidence intervals. Clinically relevant, plausibly 
important grouping variables were included in the model: SE type 1, SE type 2, 
Epilepsy, Scene at SE onset, Initial treatment before EMS and First ED. First ED was 
removed from the models, if it was chronologically irrelevant.  
Study III 
The normality of variables was tested with the Kolmogorov-Smirnov test. For the 
non-normal data, the Spearman’s correlation coefficient and, for normally 
distributed data, the Pearson’s correlation coefficient were calculated to find out 
correlation between continuous variables. Bootstrap resampling (1000 samples) 
was used to calculate the bias corrected percentile confidence intervals for 
correlation coefficients. Statistical significance of the differences in variables 
between independent samples was tested with the nonparametric Wilcoxon-
Mann–Whitney test. Differences in categorical variables were examined using the 
Fisher’s exact test. The Kaplan-Meier analysis with the log-rank test was used to 
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analyze time-to-event data. Linear regression analysis with bootstrap resampling 
(5000 samples) was used to model delays in treatment response.  
Study IV 
The Mann-Whitney test was used to find out differences in continuous variables. 
Logistic regression analysis was used to find out risk factors/delays for each 
outcome. Log transformation was used for time variables in logistic regression 
analysis. Bootstrap resampling (1000 samples) was used to calculate bias 
corrected percentile confidence intervals for odds ratios. Receiver operating 
characteristics (ROC) curves were created, and optimal cut-off values were 
calculated by maximizing the Younden’s index.  
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4 RESULTS 
4.1 Validity of data 
Reporting bias of time points in this retrospective study was controlled with 
careful evaluation of the coverage and accuracy of data obtained from the medical 
documents. Table 7. shows average LWAS and DA values in studies I-IV.  The overall 
precision of recording practices and delay data coverage is considered acceptable, 
based on the evaluation of the data availability (mean DA = 93.7 – 98.3%) and 
accuracy (mean LWAS = 1.4 - 1.6). The latter indicates data accuracy with less than 
5 min deviation from the absolute accuracy. LWAS and DA values improved during 
the SE period, in pre-hospital phase LWAS ranged from 1.4 to 2.3, whereas in-
hospital recordings it approached LWAS=1.  
 Average accuracy (LWAS) and availability (DA) of the data in studies I-IV. 
 
Missing data consisted mainly of category “events missing”. Because of the 
heterogeneity of the course of SE/GCSE, not every patient needed anesthesia, 
obtained BS or was treated in ICU. Onset-to-alarm, onset-to-initial-treatment and 
onset-to-first-ED times were missing in some patients due to timing of the events 
during the pre-status period. Unknown data concerned only single parameters for 
a few patients. 
4.2 Patient characteristics 
Basic patient characteristics, SE etiologies and predisposing factors, as well as 
parameters regarding SE type-, patient- and SE episode- related factors and 
outcome are presented in Table 8. and 9.  
 
LWAS DA
Study I 1,4 93,7
Study II 1,6 95,4
Study III 1,6 97,4
Study IV 1,5 98,3
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 Characteristics of SE (I-II) and GCSE (III-IV) patients. Values marked with (*) are 
corrected values and different compared to original articles. (Part 1/2) 
 
 
VARIABLE
N % N %
All 82 100 70 100
PATIENT CHARACTERISTICS
AGE Mean 55 54,3
Range 16-85 16-85
GENDER Male 42 51 35 50,0
Female 40 49 35 50,0
MEDICAL HISTORY Previous recorded illnesses 81 98,8 70 100
Epilepsy 51 62,2 46 65,7
ETIOLOGIES Epilepsy 52 63,4 46 65,7
Acute brain disorder 11 13,4 7 10,0
Prior brain disorder 8 9,8 7 10,0
Unknown 12 14,6 10 14,3
PREDISPOSING FACTORS Inappropriate epilepsy medic 19 23,2 16 22,9
Alcohol 12 14,6 11 15,7
Physical / emotional stress 10 12,2 10 14,3
Hyponatremia 6 7,3 5 7,1
Systemic febrile infection 5 6,1 5 7,1
Sleep deprivation 2 2,4 2 2,9
Other 9 11 6 8,6
SE TYPE RELATED FACTORS
SE type 1 CSE 74 90,2 70 100
NCSE 8 9,8 0 0
SE type 2 GSE 76 92,7 70 100
Focal 6 7,3 0 0
Pre-status period Yes 15 18,3 14 20
No 67 81,7 56 80
SE onset Continuous 54* 64,6 45 64,3
Intermittent 28* 34,1 25 35,7
PATIENT RELATED FACTORS
Epilepsy Yes 51 62,2 46 65,7
No 30 36,6 23 32,9
Age under 65 Yes 60 73,1 51 72,9
No 22 26,8 19 27,1
Living Home 28 34,1 20 28,6
Home with someone else 35 42,7 32 45,7
Nursing home 17 20,7 16 22,9
SE (I-II) GCSE (III-IV)
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 Characteristics of SE (I-II) and GCSE (III-IV) patients. Values marked with (*) are 
corrected values and different compared to original articles. (Part 2/2) 
VARIABLE
N % N %
All 82 100 70 100
SE EPISODE RELATED FACTORS
Scene at SE onset Home 37 45,1 31 44,3
Healthcare unit 32 39 28 40
Public place 13 15,9 11 15,7
SE onset at home, pt living a Yes 13 15,9 9 12,9
No 23 28 21 30
Initial treatment before EMS Yes 20 24,4* 18 25,7
No 54* 65,9 46 65,7
Rectiol as initial treatment Yes 23 31,7 23 37,1
No 54 67,1 44 62,9
Effect of the initial treatmentYes 17* 20,7 17 24,3
No 45* 59,8 39 55,7
Spontaneous cessation 15* 19,5 11 15,7
First ED Tertiary hospital 58 70,7 51 72,9
Other hospital 24 29,3 19 27,1
Pre-hospital diagnosis Yes 27* 29,3 26 37,1
No 53* 69,3 43 61,4
Pre-hospital anesthesia Yes 26 31,7 24 34,3
No 45 54,9 38 54,3
Anesthetic treatment No Anesthesia 11 13,4 8 11,4
Only Propofol 61 74,4 56 80
Multiple Anesthetics 10 12,2 6 8,6
STESS 0 3 3,7 0 0
1 2 2,4 0 0
2 35 42,7 35 50
3 19 23,2 16 22,9
4 12 14,6 10 14,3
5 9 11 9 12,9
6 2 2,4 0 0
Refractoriness Non-RSE 11 13,4 8 11,4
RSE 31 37,8 30 42,9
SRSE 40 48,8 32 45,7
OUTCOME  PARAMETERS
Condition at discharge Worse 48 58,5 41 58,6
Baseline 33 40,2 29 41,4
GOS at discharge ≤3 34 41,5 28 40
>3 47 57,3 42 60
Mortality at discharge Yes 7 8,5 5 7,1
No 75 91,5 65 92,9
SE (I-II) GCSE (III-IV)
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In studies I and II 70 cases (85.4%) presented with GCSE, 4 cases (4.9%) with focal 
convulsive SE and 8 cases (9.8%) with non-convulsive SE (6 generalized and 2 focal). 
71 cases (86,6%) had SE refractory to first- and second-stage treatment. 18.3% of 
the cases presented with sporadic seizures preceding SE onset. 
  
In 37 cases (45.1%) SE onset occurred at home, in 32 cases (39%) in a healthcare 
unit and in 13 cases (15.9%) in a public place. SE onset occurred outside the 
hospital in 74 cases (90.2%). EMS unit was called after the onset of SE in 67 (81.7%) 
cases. Among the rest of the cases, alarm call was made during the pre-SE period 
or the patient was already in hospital or arriving at the first ED otherwise. In 18 
cases (21.9%) a physician-staffed rescue unit was recruited in addition to a normal 
EMS unit for quick intubation or induction of third-stage treatment. In 24 cases 
(29.3%) the first ED was hospital ED other than HUCH and these cases were later 
transported to tertiary hospital ED in HUCH. 10 out of these cases (41.7%) found 
their way independently to first ED or were transported by ambulance to the first 
ED during pre-SE period. 14 cases (58.3%) had ongoing SE, when they were 
transferred to other hospital ED, these cases included SE presenting with 
intermittent convulsions or unconsciousness. 
 
For 78 SE cases (96.3%) the initial medication was first-stage medication and every 
third patient received it in rectal formulation. 61 out of the pre-hospital onset SE 
cases (82.4%) were medicated out-of-hospital. 20 cases of all cases (24.4%) 
received initial medication before EMS arrival, mainly in healthcare units. GCSE 
cases received average initial doses of 8.2 mg diazepam or 2.1 mg lorazepam. 62 
cases (88.6%) were medicated with additional doses of up to 29.5 mg of diazepam 
or 6.5 mg lorazepam before intensifying the treatment to second- or third-stage 
medications. 77 SE cases (93.9%) were treated with second-stage medication. 35 
cases (45.5 %) received second-stage medication before anesthesia, whereas 32 
cases (41.6 %) received it after induction of the anesthesia. 71 SE cases (86.8%) 
were anesthetized, all receiving propofol. 8 cases (11.2%) needed change of 
anesthetic agent. 53 cases (64.6 %) had only one anesthesia period, while 18 cases 
(22.0 %) needed more than one period because of withdrawal seizures and 
ongoing SE. Anesthetic treatment was inducted out-of-hospital in 26 cases (31.7%).  
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SE diagnosis was made on clinical grounds in 74 cases (90.2%) and based on EEG 
in 8 cases (9.8%). The diagnosis was reached pre-hospitally in 27 (29.3%) cases, in 
10 cases by paramedics. EEG was recorded in 67 cases (81.7 %): eight (11.9 %) for 
diagnosis and the rest for verification of treatment response. Continuous EEG-
monitoring was available for 50 cases (70.4% in the anesthetized cases).  
 
Mortality was 8.5% among all types of SE patients. Five out of the seven deceased 
patients died of direct effects of SE. Two died of complications, pneumonia and 
PRIS. At hospital discharge five patients (6.1%) remained unconscious. In 40.2% of 
SE cases the patient´s condition returned to baseline and in 57.3% of the cases the 
condition was considered good (GOS>3). 29 cases (35.4 %) were discharged to 
home, 45 cases (54.9 %) needed rehabilitation in another hospital or nursing home 
and for one case the data was not available. 
4.3 Delays (I) 
The clinical course of SE was systematically analyzed and main delay components 
were defined as delays in the treatment and treatment response delays. Delays in 
the treatment were subdivided into pre-hospital, diagnostic and treatment delays. 
Also, specific periods in the treatment course of SE were defined. The lengths of 
the individual delay components are presented in Table 10. Also, the delays of the 
GCSE patients, handled in studies III and IV, are presented here. 
  
Median 47 minutes of the 2h 2min pre-hospital period elapsed before the EMS 
arrived at the scene. Median 75 minutes were spent on treatment procedures on 
site and transportation to the ED. The time of EMS arrival after the alarm covered 
only 7% (median 9 min) of the total pre-hospital delay. A considerable extra delay 
was generated in cases needing a physician-staffed unit. 
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 Median delays in the management of SE (I-II) and GCSE (III-IV). Values marked 
with (*) are corrected values and different compared to original articles. 
 
The diagnostic delay was significantly longer in cases diagnosed by EEG than in 
cases diagnosed on clinical grounds (p<0.0001). The delay in recording the EEG did 
VARIABLE
N % TIME N % TIME
ALL 82 100 Median Range 70 100 Median Range
DELAYS IN THE TREATMENT
PRE-HOSPITAL DELAYS
Onset-to-alarm (Standard Ambulance) 67* 81,7* 0:38 00:00 - 57:44 60 85,7 0:36 00:00 - 57:44
Physician staffed rescue unit 18* 21,9* 1:15 00:03 - 05:00
Alarm-to-EMS (Standard Ambulance) 67* 81,7* 0:09 00:00 - 00:45
Physician staffed rescue unit 18* 21,9* 0:20 00:05 - 00:48
Onset-to-first-ED 70* 85,4* 2:02 00:00 - 58:29 62 88,6 2:02 00:00 - 58:29
EMS-arrival-to-first-ED 67* 81,7* 0:59 00:10 - 03:02
Onset-to-tertiary-hospital (HUCH) 82 100,0 2:25 00:37 - 277:40 70 100 2:25 00:37 - 277:40
DIAGNOSTIC DELAYS
Onset-to-diagnosis 82 100,0 2:10 00:06 - 70:40 70 100 1:48 00:06 - 60:06
Clinical diagnosis 74 90,2 1:50 00:06 - 60:06
Diagnosis based on EEG 8 9,8 13:20 2:55 - 70:40
Onset-to-EEG 67 81,7 22:02 2:30 - 142:00 57 81,4 21:52 2:30 - 142
Diagnostic EEG 8 9,8 15:30 5:20 - 70:40
Treatment response EEG 59 72,0 22:32 2:30 - 142:00
Onset-to-EEG-monitoring 50 61,0 12:00 2:30 - 82:14 42 60,0 11:10 2:30 - 82:14
HUCH-ED-to-cEEG 50 61,0 7:30 1:30 - 27:40
Anesthesia-to-cEEG 50 61,0 5:59 00:30 - 29:55
HUCH-ED-to-etiological-investigation
CT of the head 73 89,0 2:34 00:26 - 64:00
MRI of the head 17 20,7 145:40 2:15 - 617:50
Lumbar puncture 30 36,6 26:55 3:55 - 134:05
Sign. laboratory finding 27 32,9 2:32 00:06 -12:15
TREATMENT DELAYS
Onset-to-initial-treatment 77* 93,9* 0:35 00:00 - 77:05 67 95,7 0:30 00:00 - 8:15
Onset-to-second-stage-medication 77 93,9 3:00 00:30 - 77:05 67 95,7 2:40 00:30 - 61:54
Onset-to-anesthesia 71 86,6 2:55 00:00 - 81:45 62 88,6 2:38 00:00 - 66:20
TREATMENT RESPONSE DELAYS
Onset-to-first-convulsion-end 82 100,0 0:55 00:01 - 63:40 70 100 0:51 00:01 - 63:40
Onset-to-Burst-suppression 38 53,5 17:30 5:05 - 137:50 30 42,9 14:42 5:05 - 137:50
Anesthesia -to-BS 38 53,5 10:31 00:00 - 132:15
Duration of first BS 38 53,5 13:00 00:30 - 40:40
Onset-to-seizure-freedom 74 90,2 5:52 00:26 - 533:15 70 100 5:15 00:26 - 533:15
RSE/SRSE cases 65 79,2 6:45 00:26 - 533:15
Non-RSE cases 9 10,9 1:52 00:32 - 59:19
Total-convulsion-time (convulsive cases) 74 90,2 1:36 00:04 - 63:51
Onset-to-consciousness 71 86,6 47:40 2:40 - 744:15 61 87,1 42:45 2:40 - 444:40
Non-RSE cases 8 9,8 7:05 1:20 - 83:22
PERIODS IN THE TREATMENT
15 18,3 2:10 00:30 – 41:00
Total-anesthesia-time 71 86,6 38:00 3:35 - 238:52 62 88,5 38:00 3:35 - 238:52
Total-ICU-time 73 89,0 64:15 7:45 - 529:30 63 90 58:40 7:45 - 520:25
HUCH-treatment-period 82 100,0 7,7 days 0,41 - 64,7 days
SE (I-II) GCSE (III-IV)
Pre-status-period 
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differ between EEGs performed for diagnostic purposes and those intended for 
treatment response evaluation. 
4.4 Pre-hospital factors (II) 
The multivariate analysis of the factors associated with delays in the pre-hospital 
management of SE is presented in Figure 3(a-f). Focal SE was significantly 
associated with long onset-to-initial-treatment (25.8h, 95%CI 0.4-60.3, p=0.049), 
onset-to-diagnosis (28.5h, 95%CI 6.2-53.3, p=0.002), and onset-to-anesthesia (36h, 
95%CI 1.5-69.0, p=0.002) times. Administration of the initial treatment before 
EMS arrival was significantly associated with long onset-to-alarm (4h, 95%CI 0.7-
7.3, p=0.024) and onset-to-first-ED (4.3h, 95%CI 1.2-8.8, p=0.036) times. Primary 
admission to a hospital other than tertiary hospital ED caused a significant delay 
in onset-to-diagnosis (8.8h, 95%CI 1.8-15.4, p=0.008) and onset-to-anesthesia 
(9.8h, 95% CI 2.6-17.8, p=0.019) times.  
 
Post Hoc analysis revealed that, if SE onset occurred in a healthcare unit, the 
delays onset-to-alarm (p< 0.001), onset-to-first-ED (p<0.001), onset-to-tertiary-
hospital (p<0.001), onset-to-diagnosis (p=0.017), and onset-to-anesthesia 
(p=0.006) were significantly longer than if SE occurred in a public place. Living at 
home with someone else was associated with shorter onset-to-tertiary-hospital 
time than living in a nursing home (p=0.023). Onset-to-initial-treatment time was 
not associated with effectiveness of the medication. On the contrary, spontaneous 
cessation of the first seizure was associated with long onset-to-initial-treatment 
time. 
 
In the univariate analysis pre-status period (p=0.031) and rectiol as initial 
treatment (p=0.011) were associated with short onset-to-initial-treatment time. 
Age under 65 was associated with short onset-to-first-ED time (p=0.040) and both 
pre-hospital diagnosis and pre-hospital anesthesia were associated with short 
onset-to-diagnosis and onset-to-anesthesia times (all p<0.001). Patients, who 
lived with someone and whose SE occurred at home, had shorter onset-to-initial-
treatment (p=0.004), onset-to-tertiary-hospital (p=0.042), onset-to-diagnosis 
(p=0.002) and onset-to-anesthesia (p=0.015) delays, than patients living alone. 
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Fig 3a. 
Fig 3b. 
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Fig 3c. 
Fig 3d. 
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Fig 3e. 
Fig 3f. 
Fig. 3(a-f). Univariate analysis of the factors related to pre-hospital delays in 
management of SE. Median delays of the patient groups selected to multivariate 
analysis and results of the multivariate analysis are also presented 
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Kaplan-Meier curve Fig. 4. shows the difference in onset-to-diagnosis time, when 
patients transported directly to the tertiary hospital ED were compared with those 
treated first in another hospital ED. These groups differed from each other also in 
terms of onset-to-second-stage-medication time (p< 0.045), and onset-to-
anesthesia time (p< 0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4. Kaplan-Meier curve showing the difference of the Onset-to-diagnosis time 
between the SE patient groups triaged primarily to tertiary hospital ED or to other 
hospital ED. 
4.5 Cessation of GCSE (III) 
Chronological correlations, correlations between onset-to-event and event-to-
treatment-response-delays (markers for cessation of SE), are shown in Table 11. 
The delays in giving the second-stage medication (p=0.027), obtaining BS (p=0.005) 
and achieving clinical seizure freedom (p =0.035) correlate significantly with the 
delay in return of consciousness. Statistically significant negative correlation 
between full-scale EEG delay and BS delay is clinically insignificant, since in 76.7% 
of the BSs were registered with cEEG before full scale EEG. 
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Onset-to-diagnosis time (h) 
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 Chronological correlations between the onset-to-event delays and  
event-to-treatment-response delays of GCSE patients. 
VARIABLE
ONSET-TO-EVENT N Coefficient 95% CI (min) 95% CI (max) P-VALUE
Onset-to-initial-treatment 28 0.005 -0.421 0.412 0.981
Onset-to-first-convulsion-end 29 0.109 -0.282 0.474 0.573
Onset-to-alarm 22 0.303 -0.176 0.666 0.171
Onset-to-diagnosis 29 0.169 -0.198 0.497 0.382
Onset-to-second-stage-medication 30 0.057 -0.345 0.421 0.765
Onset-to-anesthesia 30 - 0.152 -0.488 0.175 0.424
Onset-to-first-ED 23 0.343 -0.062 0.732 0.109
Onset-to-tertiary-hospital (HUCH) 30 0.113 -0.247 0.498 0.552
Onset-to-EEG 26 -0.753 -0.914 -0.473 <0.001
Onset-to-EEG-monitoring 30 -0.183 -0.579 0.278 0.332
Onset-to-Burst-suppression
Onset-to-clinical-seizure-freedom
VARIABLE
ONSET-TO-EVENT N Coefficient 95% CI (min) 95% CI (max) P-VALUE
Onset-to-initial-treatment 65 -0.095 -0.344 0.156 0.453
Onset-to-first-convulsion-end 68 -0.112 -0.360 0.136 0.362
Onset-to-alarm 55 0.020 -0.253 0.295 0.883
Onset-to-diagnosis 68 -0.069 -0.321 0.226 0.574
Onset-to-second-stage-medication 66 -0.046 -0.323 0.265 0.713
Onset-to-anesthesia 61 -0.057 -0.333 0.211 0.662
Onset-to-first-ED 60 -0.022 -0.296 0.271 0.870
Onset-to-tertiary-hospital (HUCH) 69 -0.037 -0.285 0.195 0.761
Onset-to-EEG 54 -0.198 -0.475 0.081 0.152
Onset-to-EEG-monitoring 41 -0.051 -0.386 0.279 0.752
Onset-to-Burst-suppression 30 0.031 -0.359 0.443 0.872
Onset-to-clinical-seizure-freedom
VARIABLE
ONSET-TO-EVENT N Coefficient 95% CI (min) 95% CI (max) P-VALUE
Onset-to-initial-treatment 56 -0.012 -0.237 0.205 0.928
Onset-to-first-convulsion-end 58 0.085 -0.173 0.322 0.528
Onset-to-alarm 47 -0.087 -0-364 0.223 0.563
Onset-to-diagnosis 59 0.037 -0.267 0.322 0.783
Onset-to-second-stage-medication 56 0.295 0.039 0.534 0.027
Onset-to-anesthesia 51 0.025 -0.251 0.330 0.859
Onset-to-first-ED 52 0.101 -0.195 0.385 0.477
Onset-to-tertiary-hospital (HUCH) 59 0.068 -0.220 0.338 0.610
Onset-to-EEG 46 -0.162 -0.420 0.116 0.283
Onset-to-EEG-monitoring 31 0.101 -0.311 0.459 0.588
Onset-to-Burst-suppression 21 0.584 0.058 0.863 0.005*
Onset-to-clinical-seizure-freedom 59 0.275 -0.036 0.563 0.035
Spearman's rho
*  Pearson's rho
EVENT-TO-BURST-SUPPRESSION
EVENT-TO-CLINICAL-SEIZURE FREEDOM
EVENT-TO-CONSCIOUSNESS
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Regression analysis of the effect of the chronological delay components on clinical 
seizure freedom and return of consciousness is presented in Table 12. Prolonged 
delay between initial treatment and second-stage treatment is associated with 
longer delays in attaining clinical seizure freedom and return of consciousness 
(p=0.021, p=0.002, respectively). Also, the time between initial treatment and SE 
diagnosis is associated with delayed clinical seizure freedom (p=0.016). 
 The regression analysis of the effect of the chronological delay components 
on markers for cessation of GCSE. 
 
Univariate analysis of the factors related to delays in cessation of GCSE and to the 
likelihood of return of consciousness showed, that SRSE cases have significantly 
longer delays in achieving clinical seizure freedom and returning consciousness 
than non-SRSE cases (p < 0.001). All the other factors remained insignificant. 
 
Patients regaining consciousness (N=60, median 3.67 h, 95% CI 1.64–5.69 h, 
DA=98%, LWAS=1.58) achieved clinical seizure freedom significantly earlier than 
patients remaining unconscious (N=9, median 41.17 h, 95% CI 14.87–67.46 h, 
DA=100%, LWAS=1.67) (p=0.022). Differences in BS delays between these groups 
did not reach statistical significance. 
VARIABLE TIME 95% CI 95% CI p
(h) min max
Intercept 9,0 -1,4 23,6 0.082
Onset-to-initial-treatment 7,8 -1,6 13,2 0,008
Initial-treatment-to-diagnosis 2,3 0,2 4,2 0,016
Intercept 8,2 -5,6 31,3 0,273
Onset-to-initial-treatment 6,6 -2,8 11,6 0,035
Initial-treatment-to-second-stage-medication 3,0 0,4 4,8 0,021
ONSET-TO-CONSCIOUSNESS
Intercept 38,1 14,8 73,4 0,008
Onset-to-initial-treatment 0,4 -15,2 8,1 0,935
Initial-treatment-to-second-stage-medication 9,7 3,9 15,8 0,002
ONSET-TO-CLINICAL-SEIZURE-FREEDOM
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4.6 Outcome (IV)  
Univariate logistic regression analysis of the delays as risk factors for GCSE patients’ 
outcome at hospital discharge is presented in Table 13. The long delay in reaching 
the tertiary hospital (p=0.034) was a significant risk factor for functional 
deterioration in relation to baseline condition. Long delays in onset-to-diagnosis 
(p=0.032), onset-to-second-stage-medication (p=0.023), onset-to-consciousness 
(p=0.027) times and long anesthetic treatment (p=0.043) were risk factors for low 
GOS score (1-3). Short delay in giving the initial AED (p=0.047), long delays in 
starting the anesthesia (p=0.003) and long delay in returning consciousness 
(p=0.008) were risk factors for in-hospital mortality.  
 
Cut-offs for the significant delays in the univariate analysis predicting poor/worse-
than-baseline condition were determined by plotting ROC-curves (Table 14. and 
Fig 5. Diagnostic delay over 2.4 hours (ODDS 3.9, 95%CI 1.4-11.0, p=0.011), delay 
in giving the second-stage-medication over 2.5 hours (ODDS 8.3, 95%CI 2.4-28.5, 
p=0.001), altered mental status or unconsciousness lasting over 41.5 hours (ODDS 
5.0, 95%CI 1.5-16.9, p=0.009) and anesthetic treatment over 45.5 hours (ODDS 5.3, 
95%CI 1.8-16.2, p=0.003) increased the risk of poor functional recovery (GOS 1-3). 
Delay over 2.1 hours before reaching the tertiary hospital increased the risk of 
worse-than-baseline condition at discharge (ODDS 3.2, 95%CI 1.2-8.8, p=0.023).  
 
In the multivariate regression analysis, none of the delays were independent risk 
factors for poor functional outcome or mortality at hospital discharge. 
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 Univariate logistic regression analysis of the delays as risk factors for poor 
outcome at hospital discharge and summary of delay parameters. (p-values <0,05 are 
bolded, p values <0,01 are marked with *) 
 
 Area under curve (AUC) and cut-offs for the significant delays. 
 
 
DELAYS Median Time Time
time IQR (h) IQR (h) IQR p ODDs Min Max p
CONDITION AT DISCHARGE
Onset-to-initial-treatment 0,5 0,78 0,5 0,86 0,6 0,67 0,598 0,9 0,4 1,7 0,721
Onset-to-diagnosis 1,8 2,77 2,0 4,08 1,5 1,48 0,146 2,1 0,6 11,3 0,223
Onset-to-second-stage-treatment 2,7 3,39 3,2 3,89 2,3 1,98 0,087* 2,6 0,5 41,8 0,247
Onset-to-tertiary-hospital 2,4 2,83 2,6 3,47 2,0 2,35 0,027 4,4 1,4 47 0,034
Onset-to anesthesia 2,6 4,04 2,3 4,48 3,2 2,33 0,256 2 0,67 7,7 0,233
Onset-to-Burst-Suppressio 14,7 19 14,9 21,79 14,0 19,27 0,632 2,3 0,1 226,8 0,461
Onset-to-seizure-freedom 5,3 46,6 5,8 49,36 4,1 35,4 0,599 1,2 0,7 2,5 0,515
Onset-to-consciousness 42,8 51 56,3 65,33 29,0 43,83 0,082* 2,5 0,8 15,2 0,095*
Total-anesthesia-time 38,0 51,23 46,8 65,57 24,0 29,81 0,059* 3,5 0,9 30,6 0,117
Total-ICU-time 58,7 106,75 67,6 111,4 50,3 90,25 0,106 2,9 0,8 12,2 0,08*
GOS AT DISCHARGE
Onset-to-initial-treatment 0,5 0,78 0,5 1 0,5 0,75 0,966 1,1 0,6 2,2 0,846
Onset-to-diagnosis 1,8 2,77 2,7 4,33 1,5 1,59 0,071* 3,4 1 20,6 0,032
Onset-to-second-stage-treatment 2,7 3,39 3,4 4,58 2,3 2,08 0,007 6,6 1,3 101,5 0,023
Onset-to-tertiary-hospital 2,4 2,83 2,4 3,95 2,1 2,21 0,074* 2,4 0,8 19,7 0,162
Onset-to anesthesia 2,6 4,04 4,3 4,84 2,3 2,29 0,048 3,1 0,92 15,2 0,059*
Onset-to-Burst-Suppressio 14,7 19 16,5 32,96 13,3 17,84 0,587 2,3 0,1 44 0,444
Onset-to-seizure-freedom 5,3 46,6 7,5 55,76 4,3 31,31 0,229 1,6 0,8 3,6 0,178
Onset-to-consciousness 42,8 51 59,9 63,77 28,5 43,67 0,032 3,6 1,1 37,7 0,027
Total-anesthesia-time 38,0 51,23 57,9 57,87 26,5 39,5 0,037 5,1 0,9 52,5 0,043
Total-ICU-time 58,7 106,75 69,7 100,17 53,3 109,88 0,114 3 0,8 12,5 0,054*
IN-HOSPITAL MORTALITY
Onset-to-initial-treatment 0,5 0,78 0,2 0,83 0,5 0,7 0,115 0,4 0 1,7 0,047
Onset-to-diagnosis 1,8 2,77 4,3 6,46 1,8 2,65 0,208 2,9 0,3 35,5 0,209
Onset-to-second-stage-treatment 2,7 3,39 3,6 4,93 2,6 2,78 0,467 1,4 0 28,2 0,741
Onset-to-tertiary-hospital 2,4 2,83 2,8 49,48 2,3 2,78 0,172 2,6 0,2 7,71E+75 0,123
Onset-to anesthesia 2,6 4,04 7,5 35,43 2,4 3,65 0,031 8,7 1,2 1,33E+03 0,003
Onset-to-Burst-Suppressio 14,7 19 22,0 18 14,0 19,08 0,22 5,1 0,6 2657,1 0,168
Onset-to-seizure-freedom 5,3 46,6 8,4 92,89 4,7 47,54 0,3 1,8 0,5 51,4 0,252
Onset-to-consciousness 42,8 51 89,3 0 40,4 50,43 0,475 6,3 3,1 30,6 0,008
Total-anesthesia-time 38,0 51,23 76,5 68,26 34,4 48,71 0,202 6,6 0,2 849,8 0,153
Total-ICU-time 58,7 106,75 65,9 115,15 58,6 111,42 0,613 1,8 0,3 15,5 0,463
For logistic regression the variables were log transformed and bootstrapped confidence intervals (CI) were calculated.
95%CI
GOS 1-3 GOS>3
Dead Alive
All Cases Worse Baseline
AUC CI 95% CI 95% p CUT-OFF Sensitivity Specificity
DELAY OUTCOME (min) (Max) (h)
Onset-to-diagnosis GOS 1-3 0,63 0,49 0,77 0,071*  2,4* 0,76 0,56
Onset-to-second-stage-medication GOS 1-3 0,693 0,56 0,83 0,008 2,5 0,59 0,85
Onset-to-tertiary-hospital (HUCH) Worse-than-baseline condition 0,657 0,52 0,79 0,028 2,1 0,71 0,57
Onset-to-consciousness GOS 1-3 0,658 0,52 0,80 0,037 41,5 0,75 0,64
Total-anesthesia-time GOS 1-3 0,676 0,54 0,82 0,032 45,4 0,66 0,72
VARIABLES
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Fig 5. Receiver operating characteristics curves (ROC-Curves) for the delays. 
Outcome variable for onset-to-diagnosis, onset-to-second-stage-medication, onset-to-
consciousness and total-anesthesia-time is low GOS score (1-3) at hospital discharge 
and for onset-to-tertiary-hospital (HUCH) is worse-than-baseline-condition. 
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5 DISCUSSION 
This retrospective cohort study reveals unacceptably long delays in the treatment 
of SE, which calls for rigorous changes in the treatment management. Streamlining 
the whole treatment chain of SE is necessary and the main focus should be on pre-
hospital management. Here delay-related factors and proposed measures to 
shorten different delays will be discussed in detail. Paucity of the studies 
concerning the effects of delays on outcome in the previous literature complicates 
comparison. 
5.1 Treatment delays 
5.1.1 Initial treatment 
The delay in giving the initial medication in our SE cohort is one of the shortest 
among the previously reported delays38,76,86,90,111,116,123,129,161,168, though not even 
close to the times recommended by the guidelines. Quickest treatment initiation 
was achieved when rectal administration of the medication was used, and 
therefore buccal midazolam, which became routine practice in EMS after the 
present patient material was collected, is expected to further shorten the 
treatment delay. Clinical appearance of SE and scene at onset seem to set the pace 
and accuracy for the treatment. Convulsion and generalization of the seizure and 
onset in a healthcare unit were significantly associated with a short delay in 
administration of the initial treatment. Also, first seizures during pre-status period 
were associated with early administration of the initial treatment, which may 
partly be due to low threshold in pre-status recruitment of EMS. 
 
Surprisingly, our study showed that short delay in giving the initial medication is 
related to in-hospital mortality and does not expedite cessation of GCSE. This 
unexpected result could be explained by the finding that although non-survivors 
received the initial treatment several times quicker than survivors, all the other 
delays were multiple compared to the survivors. Additionally, an initial treatment 
given early, before EMS arrives, resulted in longer onset-to alarm and onset-to-
first-ED times, as compared to the group, whose initial treatment was given after 
EMS arrival. The same phenomenon was seen in the healthcare unit-onset group 
with short onset-to-initial-treatment time but otherwise delayed actions. These 
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findings may reflect the risk involved in partial treatment response, i.e., false sense 
of security after the first given medication. We demonstrate that adequately 
started pre-hospital initial treatment does not necessarily mean short delays in 
other parts of the treatment chain, if the continuum of the treatment is hampered 
by a failing recognition of SE. Taken together, these observations point out that 
short initial treatment delay per se does not lead to a better outcome, unless the 
whole pre-hospital chain of recovery is optimized and therefore a (local) 
standardized pre-hospital management protocol upon established SE cases should 
be generated. 
 
5.1.2 Second-stage treatment 
The delay in giving second-stage treatment observed in our study, median 3 h, is 
somewhat longer than those in previous reports111,116 and may partly be due to 
the fact, that second-stage treatment was not available in EMS by the time of 
material collection. In our recruitment area, if the first-stage medication given out-
of-hospital failed, the general practice was intubation and initiation of third-stage 
treatment, as happened in over 40 % of our cases. 
 
In this present study, onset-to-second-stage medication delay was correlated with 
delay in return of consciousness in GCSE patients. Prolonged time between initial 
treatment and second-stage treatment predicted delayed clinical seizure freedom 
and return of consciousness. Additionally, delayed second-stage treatment was 
associated with poor outcome at hospital discharge. Since this study material is 
nearly homogeneous in terms of the agent used, iv-phosphenytoin, it seems even 
more essential to minimize second-stage medication delay in order to improve the 
patients’ outcome. 2.5 hours as the prognostic cut-off in giving second-stage 
medication should direct the focus of streamlining the treatment protocol in the 
pre-hospital phase.  
 
We propose that administration of second-stage agents already by EMS out-of-
hospital could reduce the delays, especially now that safety, tolerability and 
storage issues regarding phosphenytoin could be bypassed by using the newer 
agents. There is no real evidence that the use of newer agents would impair the 
prognosis188-190 and therefore it is possible that any second-stage agent given in 
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adequate doses during the first 2.5 hours might improve the outcome. Naturally, 
an adequate evaluation of the patient by a physician should be obtained to 
ascertain the correct diagnosis before the medication and to maximize patient’s 
safety during the medication.   
5.1.3 Third-stage treatment 
In our material 50 % of the cases were anesthetized within 3 h, which equals to 
previous reports111. Median duration of IVAD treatment was also consistent with 
the literature34,102,112. The anesthetic used was mainly propofol, which was well 
tolerated, and although one complication of PRIS (death) was seen, in 90 % of the 
cases propofol led to the intended response. Prognostic cut-off of total-anesthesia 
time (45.4h) was not exceeded, which may have had a positive impact on the 
tolerability. 
 
Long delays in starting third-stage treatment were significantly associated with in-
hospital mortality and had a trend-like association with poor outcome. Therefore, 
IVADs should be initiated as early as possible after the first-, and second-stage 
treatments fail. GCSE patients with previously diagnosed epilepsy seemed more 
likely to have short delays in starting anesthesia as compared to other SE types. 
Therefore, recognition and diagnostic procedures of seizures other than GCSE 
should be improved by e.g. applying EEG on site. 
 
SE onset at a public place, SE diagnosed out-of-hospital and transportation of 
patients directly to tertiary hospital ED were associated with short delays in 
initiation of anesthesia. Therefore, procedures of the pre-hospital phase of the 
treatment should be in focus when streamlining the protocols. 
 
Although IVAD treatment for almost two days predicts poor functional outcome at 
hospital discharge, it does not mean that the IVAD treatment should be limited to 
less than two days in all patients. Targeting IVADs quickly to right patients and 
preventing or minimizing complications during IVAD treatment seem to be 
essential in the prognosis of IVAD-treated patients. 
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5.2 Pre-hospital delays 
Nearly half of the two-hour prehospital delay elapsed before the emergency 
service arrived at the scene and the rest was used for treatment at the scene by 
paramedics and for transportation to the hospital. Long delay in calling the 
ambulance exceeded previous reported delays only to a small extent76,161 and may 
partly be explained by patient-related factors, such as alcohol abuse (15 % of cases) 
and patient living alone, as also reported in stroke studies208. However, we think 
that this delay predominantly reflects lack of fluency in pre-hospital management. 
SE onset in a healthcare unit and treatment initiation before calling the ambulance 
resulted in exceedingly long delays in calling the ambulance and reaching EDs, 
although treatment initiation was managed without delay. This may reflect an 
inborn source of delay: once the treatment is started, it automatically leads to 
delays caused by assessment of the treatment response and, if unresponsive, 
further treatment attempts in the same unit. Such delays naturally do not occur in 
a public place. These results accentuate the need to further improve education on 
appropriate timing of contact with EMS. In Finland patients diagnosed with 
epilepsy and their care-takers have received a standard instruction to call 
emergency service as soon as a seizure prolongs over 5 min or the patient does 
not recover normally after the seizure. The current results suggest further need 
for education among professionals, as well.  
 
Long delay in reaching the tertiary hospital was associated with worse-than-
baseline condition at discharge in this current study. The median onset-to-first-ED 
time of all patients and that of patients transported straight to the tertiary hospital 
did not diverge markedly. Thus, an effective treatment in hospital could have been 
started with similar delay for both groups. However, it took four times longer for 
80 % of the patients to be diagnosed with SE, and significantly longer delays in 
starting second- and third-stage medications, if the patient was triaged to a 
hospital other than tertiary hospital. We conclude that treating SE patients in EDs, 
where the neurologist bears the main responsibility 24 hours a day, and where 
EEG is more often available, may lead to better quality of treatment and better 
prognosis. The prognostic cut-off of slightly over 2 hours in reaching tertiary 
hospital calls for prompt recognition of SE and direct transportation of even 
suspected SE cases to tertiary hospital. Only if physician-staffed units at scene 
could make the diagnosis and start efficient second- and third-stage medications, 
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the importance of the time between onset of SE and admission to tertiary hospital 
ED might be less important, as also stated in cardiac infarction studies211. More 
frequent recruitment of physician-staffed rescue units upon the primary alarm 
with highest priority and qualification of paramedics to intubate and stabilize the 
patient already at the scene would also help eliminate the significant extra delay 
caused by second alarm for a physician-staffed unit, as seen in this study. 
5.3 Diagnostic delays 
The median delay of SE diagnosis in this material was over 2 hours, whereas the 
diagnostic delay of GCSE patients remained under 2 hours, mainly due to the fact, 
that almost all of GCSE cases could be diagnosed on clinical grounds. Diagnostic 
delay was associated with low GOS score at hospital discharge and a prognostic 
cut-off for the delay lay at little over two hours. Although diagnostic delay did not 
affect the duration of SE, short time between initial treatment and SE diagnosis 
was associated with early seizure freedom. Therefore, shortening the diagnostic 
delay is crucial to improve the patients’ outcome and to ensure rapid and 
adequate treatment of SE. 
 
Previously diagnosed epilepsy, onset at a public place and primary transportation 
to tertiary centre were related to shorter diagnostic delays, whereas focal SE and 
NCSE, for which availability of EEG is essential for diagnosis, were associated with 
long delays. Easier recognition of convulsive SE is obvious. Severity of the patients’ 
general condition may also lead to accelerated actions in the pre-hospital 
management, as seen in stroke studies202,204,205. Awareness of the risk of SE among 
epilepsy patients may facilitate SE diagnosis, but quicker diagnosis in tertiary 
hospital may reflect insufficient level of awareness of SE in primary and secondary 
health care units, which lack neurologists and EEG service and which do not treat 
SE patients on regular basis. Rapidity of diagnosis among public-onset cases may 
simply reflect the fact that majority of those patients were transported directly to 
tertiary hospital. 
 
Improvement of EEG availability is indispensable for improving diagnostics of SE, 
since in our cohort diagnostic EEG could not be performed more urgently than EEG 
for response verification purposes. Routinely applied continuous EEG monitoring 
for hospitalized SE patients would serve both diagnostic and monitoring purposes. 
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Out-of-hospital eEEG using a rapidly applicable electrode cap and telemedical 
connection to the hospital might provide a method to facilitate the diagnosing 
process on site. Presently, this suggestion remains speculative, since studies on 
eEEG at emergency site are lacking. However, major attempts should be made to 
enable recordings at the scene, since the technology is available.  
 
Increasing the common knowledge of the risk of SE upon acute seizures among 
laymen, ambulance dispatchers in emergency phone call centres, EMS and 
hospital personnel, generating simplified criteria for suspicion of an imminent SE, 
transporting SE patients primarily to tertiary hospital and improving EEG 
availability should be considered as measures to cut down diagnostic delays. 
5.4 Treatment response delays 
A stepwise definition for treatment response was created for this study in order to 
characterize the extinction of SE. This included clinical seizure freedom for 
convulsive cases, obtaining BS for anesthetized cases and return of consciousness 
for all cases, the latter being the only reliable clinical marker for the end of GCSE. 
Comparison of our results with previous studies is hampered by the problems in 
defining the end of SE, as described in detail in review of the literature.  
 
All GCSE cases in our cohort reached the point of clinical seizure freedom during 
the SE period, the delay of which was nearly equal to previous reported ones27. 
75 % of the cEEG-monitored patients achieved BS, which was maintained for 12–
24 hours, in accordance to current European guidelines147. However, the delays in 
obtaining BS did not reach the time frames recommended by the guidelines, 
reflecting the clinical reality. The delay in obtaining BS after the start of anesthesia 
was median 10 hours and accounted nearly half of the total onset-to-BS time. In 
prospective settings anesthesia-to-BS delay was only 30 minutes regardless of the 
anesthetic agent223,224, demonstrating that treatment response delays could be 
significantly shortened by an acknowledged management protocol and highly 
trimmed ED team.  
 
We found a significant correlation between early administration of second-stage 
medication, early clinical seizure freedom, early BS and early return of 
consciousness. Correlations regarding clinical seizure freedom and BS serve as a 
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validation of the stepwise definition for the end of SE. Since nearly half of our 
patients seemed to benefit from early BS, the question remains, whether the 
proportion of patients with returning consciousness would increase, if third-stage 
treatment leading to BS would be given in recommended time frames. To our 
surprise, onset-to-initial-treatment time, onset-to-diagnosis time, and onset-to-
anesthesia time were not correlated to markers for cessation of GCSE, nor were 
the previously established outcome predictors.  
 
Return of consciousness was associated with favorable outcome at hospital 
discharge. Long delay in onset-to-consciousness was related to poor functional 
outcome at discharge and in-hospital mortality, which is concordant with a 
previous study defining the end of SE with clinical recovery104. All effort in the 
management of SE should be made to expedite regaining of consciousness as soon 
as possible, since slightly less than two days of unconsciousness seems to be a 
critical time point for the prognosis after SE.  
5.5 Strengths and limitations of the study 
To our knowledge this is the first study evaluating systematically the delays in the 
treatment of SE over the whole treatment chain and investigating sequentially the 
interdependence of the delays and other factors, and their impact on outcome. 
Retrospective nature of the present study characterizes the clinical reality in SE 
management, elucidates the difficulties in the treatment chain and enables 
plausible target setting for protocol streamlining in the future. Abundant pre-
hospital patient data were available for each case. Data on time-related 
parameters was made transparent by careful evaluation and documentation of the 
coverage and accuracy of delays obtained from the medical documents. However, 
reporting bias due to inaccurate original recording remains undefined and beyond 
the control of the research team. 
 
This study encompasses some limitations, which may require caution, when 
interpreting and generalizing the results. Study material includes a limited number 
of patients from a single tertiary centre and presents data on mainly non-normally 
distributed parameters. In studies III and IV only patients with GCSE were included 
to increase the uniformity of the material. The operational definition of SE has 
changed since the material collection and therefore SE patients with seizure 
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duration of 5 to 30 minutes are not included in the study. However, main 
characteristics of the material (seizure type, etiologies, age distribution) are 
similar to previously SE published materials. It is remarkable, that the present 
material weighs toward RSE/SRSE slightly more than previously published ones. 
This might relate to the changed definition, but another explanation may be that 
HUCH as a tertiary center collects the most severe cases of SE or that cases with 
prolonged seizure responding to the first-stage treatment may have missed the 
diagnosis of SE and are therefore not included in this study. 
 
We also recognize that this study material is rather old. Yet, it is still representative 
of present-day SE management, since during the last decade no major treatment 
protocol reformations have been proposed. Rather, less options for AEDs at the 
time of the material collection and principal use of phosphenytoin as the second-
stage-medication reduce bias due to medication heterogeneity. 
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6 CONCLUSIONS AND RECOMMENDATIONS 
This retrospective cohort study reveals the clinical reality in the treatment of SE. 
After the systematic analysis of delay components in the treatment chain, we 
found unexpectedly and unacceptably long median delays with a wide range, and 
acknowledge the need to shorten them markedly (I). These long delays might be 
related to the remarkable inadequacy detected in recognition of SE both among 
laity and medical professionals, and suboptimal triaging of SE patients. There is an 
obvious need for increasing awareness of imminent SE and streamlining the pre-
hospital management of established SE. SE should be given a compeer position 
with stroke and cardiac infarction and acknowledged as a medical emergency with 
similar resource allocation in the pre-hospital management (II). 
 
Delays in the treatment chain might be more significant determinants of GCSE 
cessation than the previously established outcome predictors (III). Nearly all main 
components of the treatment chain have significant associations with functional 
outcome and mortality at hospital discharge. However, none of them seem to be 
independently associated with outcome, which impresses the dynamism of the 
treatment of GCSE (IV). Therefore, streamlining the whole treatment chain of SE 
is advocated, although the main focus should be on pre-hospital management. 
 
According to the results of this thesis, the following amendments to the 
management protocol of SE are recommended:  
 
? Triaging suspected SE cases with highest priority 
? Recruiting physician-based EMS units upon primary alarm 
? Qualification of paramedics to intubate and stabilize the patient already at the 
scene 
? Administration of second-stage medication out-of-hospital 
? Standardized pre-hospital management protocol for established SE 
? Transportation of SE patients exclusively to hospitals with neurological 
expertise 
? Generation of simplified criteria for suspicion of an imminent SE applicable 
both out-of-hospital and in health care units 
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We further advocate: 
  
? Investigation of diagnostic possibilities on emergency site  
? Increased education to improve common knowledge of the risk of SE among 
acutely seizing patients 
 
We suggest that delays are considered as endpoints in planning future prospective 
study protocols, which should include matched patient groups. 
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